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ABSTRACT 
 
Each year, influenza is the cause for many cases of illness and deaths worldwide. Due to the virus’ 
fast mutation rate, the World Health Organization (WHO) is constantly on alert to be able to 
respond rapidly in the case of the emergence of a pandemic strain. Although anti-viral therapies 
exist, the most proficient way to stop the spread of disease is through vaccination. The majority 
of influenza vaccines on the market are produced in embryonic hen’s eggs and are composed of 
purified viral antigens split from inactivated whole virus. This manufacturing system, however, is 
limited in its production capacity, especially in the case of a pandemic, producing approximately 
one vaccine dose per egg. Additionally, the process from strain identification to vaccine release is 
about 6 months, which is relatively long especially if a vaccine is urgently needed. 
For this reason, cell culture processes for vaccine production are a topic of interest amongst the 
vaccine industry to better respond to the threat of a potential influenza pandemic. Recently, the 
FDA, supporting the basis for this research, has approved two cell culture based vaccines, the 
first produced in mammalian cells and the second in insect cells using recombinant technology.  
Virus-like particle (VLP) vaccines are one of the most promising approaches to respond to the 
constant threat of the emergence of pandemic strains. VLPs are particles produced in cell culture 
utilizing recombinant protein technology composed of viral antigens that can elicit immune 
response but lack viral genetic material. Most of the work done on influenza VLPs have focused 
on the immunological aspects of VLPs with little attention paid to bioprocessing, in particular the 
scalability of the production methods. Another challenge stems from the fact that researchers 
have used standard influenza virus quantification techniques up to this point to characterize VLP 
vaccine candidates, as they are suitable methods to use for purified samples. These methods, 
however, are not suitable for in-process analysis of samples, which is generally the case for 
process development. As a result, process development is quite challenging without an 
appropriate quantification method, which is one reason this avenue has not been fully explored. 
Past influenza VLP studies have been mainly performed in the baculovirus expression vector 
system (BEVS) in insect cells and report contamination with recombinant baculovirus. However, 
baculovirus with mammalian promoters (Bacmam) have been shown to efficiently transduce 
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mammalian cells and further express genes under mammalian promoter control but are unable to 
replicate, efficiently repressing contaminating baculovirus production.  
In order to address the issue of baculovirus contamination, VLP production was performed in 
HEK 293 suspension cells using the Bacmam gene delivery system. The proposed system was 
assessed for its ability to produce influenza VLPs composed of Hemagglutinin (HA), 
Neuraminidase (NA) and Matrix Protein (M1) and compared to VLPs produced in Sf9 cells 
through the lens of bioprocessing. VLPs from both systems were characterized using currently 
available influenza quantification techniques such as single radial immunodiffusion assay (SRID), 
HA assay, negative staining electron microscopy (NSEM) and western blot. VLPs were found to 
be associated with the cell pellet in HEK 293 production in addition to in the supernatant. It was 
found that VLP production in Sf9 cells produced 1.5 logs more VLPs than in HEK 293. Sf9-
VLPs had higher total HA activity and were generally more homogeneous in morphology and 
size. However, Sf9 VLP samples contained 20 times more baculovirus than VLPs. Baculovirus 
can contribute to HA activity in both the HA assay and SRID, which should be acknowledged 
during process development stages. This study shows the strength of the insect-cell baculovirus 
system for VLP production when compared to proposed alternatives in HEK 293 cells from the 
bioprocessing point of view but also highlights that there is a major need for baculovirus removal 
to properly characterize and consider them as vaccine candidates. 
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RÉSUMÉ 
Chaque année, le virus de l'influenza est responsable d'un grand nombre de maladies et décès. 
Aux vues de la fréquence élevée de mutation du virus, l'Organisation Mondiale de la Santé 
(OMS) est en alerte permanente afin de répondre rapidement à toute émergence d'une souche 
pandémique. Bien que des thérapies anti-virales existent, la méthode la plus efficace contre toute 
propagation de la maladie est la vaccination. La majorité des vaccins disponibles sur le marché 
sont produits dans des oeufs et sont composés d'antigènes viraux purifiés séparés des virus entiers 
inactifs. Le système de production n'est cependant pas adapté à une situation de pandémie, la 
capacité étant limitée à une dose de vaccin par oeuf. Aussi, l'intervalle de 6 mois entre 
l'identification de la souche virale et la production du vaccin est trop longue pour envisager 
répondre de manière adéquate à la case l’émergence d’une pandémie. 
Pour ces raisons, les procédés de production de virus par culture cellulaire peuvent permettre de 
répondre de manière adéquate à une pandémie potentielle. Récemment, la Food and Drug 
Administration (FDA) a approuvé deux vaccins produits par culture cellulaire, le premier étant 
produit dans des cellules de mammifère tandis que le second est produit de manière recombinante 
dans des cellules d'insecte. 
Les vaccins à base de particules pseudo-virales (PPVs) représentent une des approches les plus 
prometteuses afin de répondre à la menace constante de l'apparition de souches pandémiques. Les 
PPVs sont des particules produites en culture cellulaire de manière recombinante et qui sont 
composées d'antigènes viraux capables d'induire une réponse immunitaire, bien que ces particules 
soient dénuées de matériel génétique viral. Alors que la plupart des travaux effectués sur les 
PPVs de l'influenza se sont concentrés sur les aspects immunologiques, peu d'études se sont 
attachées au procédé de production lui-même, et en particulier à son adaptation à une production 
industrielle. Une autre difficulté résulte du fait que les chercheurs ont jusqu'à présent utilisé des 
méthodes standards de quantification du virus de l'influenza afin de caractériser les vaccins 
potentiels, ces méthodes étant compatibles pour la quantification d'échantillons purifiés. Elles ne 
sont pas compatibles, cependant, avec l'analyse d'échantillons durant le procédé de production. 
C'est une des raisons pour lesquelles l'étude du procédé de production lui-même reste à accomplir. 
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Les études précédentes sur les PPVs de l'influenza ont été principalement effectuées dans des 
cellules d'insecte en utilisant le système d'expression du baculovirus (BEVS). Ces études ont 
également démontré une contamination par le baculovirus recombinant. Cependant, il a été 
également démontré que le baculovirus comprenant des promoteurs de mammifères (Bacmam) 
est capable de transduire de manière efficace des cellules de mammifères et d'exprimer 
ultérieurement des gènes sous le contrôle de promoteurs de mammifères. Un tel baculovirus est 
ainsi incapable de se répliquer, ce qui réprime de manière efficace la production contaminante de 
baculovirus.  
Afin de remédier à une possible contamination par le baculovirus, la production de PPVs a été 
effectuée dans des cellules HEK 293 cultivées en suspension en utilisant le système Bacmam. Le 
système fut évalué pour sa capacité de production PPVs de l'influenza composées 
d'hémaglutinine (HA), de neuraminidase (NA) ainsi que de protéines matricielles (M1). Ces 
PPVs ont ensuite été comparées à des PPVs produites dans ces cellules Sf9. Les PPVs des deux 
systèmes ont été caractérisées avec les méthodes de quantification présentement disponibles : test 
SRID (single radial immunodiffusion assay), test d’hémagglutination, microscopie électronique 
en coloration négative et western blot. Les PPVs étaient présents dans le culot ainsi que dans le 
surnageant dans la production pour les cellules HEK 293. Dans les cellules Sf9, la production de 
PPVs était 1.5 log plus importante que dans les cellules HEK 293. Les PPVs produites dans les 
cellules Sf9 avaient une activité totale HA plus importante et étaient de manière générale plus 
homogènes en termes de morphologie et taille. Cependant, les PPVs produites dans les cellules 
Sf9 contiennent 20 fois plus de baculovirus que de PPVs, ce qui peut contribuer à l'activité 
détectée dans les tests HA et SRID. Cette conclusion doit être prise en compte au cours du 
développement du procédé de production.  
Cette étude démontre les avantages du système de baculovirus pour la production de PPVs dans 
les cellules d'insecte par rapport à de la production dans les cellules HEK 293. Cette étude 
démontre également qu'une purification du baculovirus contaminant est également nécessaire 
avant de pouvoir considérer ces PPVs comme des vaccins potentiels. 
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1 
INTRODUCTION 
Context 
 
Each year, influenza is responsible for approximately 500 million cases of infection and between 
250,000 to 500,000 deaths due to seasonal epidemics (WHO, 2009), as reported by the World 
Health Organization (WHO). Currently, vaccination remains the most proficient strategy to 
prevent infection and to battle the persistent threat of influenza epidemics. Egg-based production 
has remained the standard method to produce seasonal influenza vaccines since the 1950s; 
however, the influenza H1N1 pandemic of 2009 has highlighted the limitations associated with 
this manufacturing method in the case of the emergence of a pandemic strain (Cohen, 2009; 
Michaelis, Doerr, & Cinatl, 2009). The main problem is the long 6-month period from strain 
isolation to final dose formulation and validation (Gerdil, 2003). Strategies to shorten the 
response time and expand production capacity are currently being investigated. Seasonal 
influenza vaccines derived from cell culture are gaining attention and in November 2012, the first 
seasonal vaccine produced in cell culture (Flucelvax, Novartis) was approved by the FDA (FDA, 
2012) for adults 18 years of age and older. Additionally, in January 2013, the first trivalent 
influenza vaccine, Flublok (Protein Science Corporation), made in insect cells using a virus 
expression system (baculovirus) and recombinant DNA technology was approved for the 
prevention of seasonal influenza in people aged 18 through 49 (FDA, 2013). These recent 
advances reflect an important trend of adopting modern cell culture manufacturing in the vaccine 
industry and is supported by public health and regulatory agencies that currently promote 
strategies to improve responses to emerging infectious diseases. 
Other strategies, such as subunit or DNA vaccines (Chua & Chen, 2010), are potential methods to 
overcome the limitations of egg-based production, but one of the most promising approaches is 
the recombinant protein based virus-like particle (VLP) vaccine (Haynes, 2009; Kang, Song, 
Quan, & Compans, 2009) 
Influenza VLPs are non-infectious and non-replicating particles, displaying intact and 
biochemically active antigens. They do not contain genetic material, but are empty particles 
composed of one or both of the two viral immunogenic antigens of influenza: HA and/or NA 
(Haynes, 2009). Additionally, influenza VLPs can be constructed with one or both of the two 
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matrix proteins, M1 and M2 (Kang et al., 2009; Pushko et al., 2005; Wu et al., 2010). Although  
NA is not a quantified antigen in final vaccine formulations, the presence of NA in influenza 
VLP constructions is advantageous, as it has been demonstrated to help in protection against 
influenza infection (Gravel et al., 2010; Marcelin et al., 2011).  
Thus far, immunizations with influenza VLPs to protect against either seasonal or pandemic 
influenza strains have shown promising results (Latham & Galarza, 2001; Pushko et al., 2005, 
2011). A general description of the different immunization trials performed thus far is presented 
in Kang et al. ( 2009). Now that more clinical trials are underway for VLP vaccines (Landry et al., 
2010; López-Macías et al., 2011), it is important for the scientific and engineering community to 
tackle the challenges still associated the bioprocessing aspects of VLP production.  Moreover, in 
order to develop robust manufacturing processes, production values (number of particles/ml, µg 
HA/ml), limiting factors (quantification methods, contamination), and product stability studies 
need to be communicated and completed.  
Thesis Organization 
 
Chapters 1-3 will give the reader background on the influenza virus, vaccines and the methods 
currently used to produce and purify influenza VLPs. Chapter 4 outlines the objectives of this 
work, and Chapter 5 describes all the methods used for experimentation. Chapters 6 and 7 present 
the results from VLP production in both Sf9 and HEK 293 platforms, and Chapters 8 and 9 are 
discussion and conclusions, respectively. The appendices provide extra material, calculations, 
raw data and a section with preliminary results for the application of VLPs on a total influenza 
HPLC detection method developed in-house.  
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Chapter 1: Influenza Virus 
1.1 Virus Characteristics 
 
The influenza virus is a single stranded RNA virus belonging to the Orthomyxoviridae family. 
Orthomyxoviruses are enveloped viruses that have the ability to bind sialic acid residues in 
mucoproteins. Influenza is made up of three different types of virus; A, B and C. Influenza type 
A, which infects avian and mammalian hosts, is the most widely studied and the cause of most 
influenza epidemics. Type B is limited to human hosts and type C infects both porcine and 
humans. Within each type of influenza, different subtypes exist based on the two surface 
glycoproteins, hemagglutinin (HA) and neuraminidase (NA). The virus’ genome is composed of 
seven or eight individually wrapped gene segments in helical nucleocapsids that are packaged 
within the virion’s envelope.  Six of the gene segments code for influenza proteins (PB2, PB1, PA, 
HA, NP, NA) and 2 of the gene segments are spliced to produce another four viral proteins (M1, 
M2, NS1 and NS2 (or NEP)) (Acheson, 2007). Influenza virus undergoes the phenomena of 
antigenic shift and drift, resulting in the emergence of mutated and new strains. Antigenic drift is 
the gradual mutation of specific strains, occurring every 2-8 years from subtle point mutations 
within the HA and NA antibody binding sites (Carrat & Flahault, 2007).  Due to annual antigenic 
drift, updated vaccines are required each flu season in the northern and southern hemispheres. 
The other phenomenon is antigenic shift, which occurs only with influenza type A viruses when 
HA (and sometimes NA) is replaced with novel types. This causes the emergence of new viral 
strains that have the potential to cause worldwide pandemics due to the population’s lack of 
immunity. It is estimated that antigenic shift occurs three times every 100 years and was the 
cause for the three major pandemics in the 20th century (1918, 1957 and 1968) (Carrat & Flahault, 
2007).  Currently there are 16 HA and 9 NA subtypes (Noda, 2011).  
1.2  Structure 
 
All viruses are composed of genetic material and viral proteins and can be classified as either 
enveloped or non-enveloped. Enveloped viruses acquire a lipid bilayer when they bud from a cell 
membrane that coats the nucleocapsids with membrane containing nucleocapsids. Most viruses 
bud from the cell plasma membrane, however some viruses bud from internal cellular membranes 
such as the endoplasmic reticulum or the Golgi membrane to acquire their envelope (Welsch, 
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Müller, & Kräusslich, 2007). Non-enveloped viruses do not bud from cellular membranes, but 
are released from the cell through lysis and therefore do not have envelopes (Acheson, 2007). 
Influenza is classified as an enveloped virus that buds from the plasma membrane. The influenza 
genome replicates in the nucleus and when HA, NA and M2 glycoproteins have been synthesized, 
they are trafficked to the plasma membrane via the Golgi network where the assembly and 
budding process begins. Currently, the main driving force for influenza virus assembly and 
budding is not exactly known but it is believed that multiple proteins possess the ability to initiate 
budding, resulting in a redundant system capable of survival even if certain proteins have lost 
their functionality (Rossman & Lamb, 2011). Each gene segment is assembled in a helical 
nucleocapsid where RNA is wrapped around the NP protein and bound at the 5’ and 3’ ends to a 
trimer of PB2, PB1, and PA. The virion is said to contain one copy of each genetic segment that 
are packaged inside. The matrix protein (M1) interacts with both the nucleocapsids and the 
plasma membrane by binding to the cytoplasmic tails of either HA, NA or M2. Additionally, it 
serves as the structural backbone of the virion and helps to maintain its morphology (Noda, 2011). 
Figure 1.1 shows the structure of an influenza virus particle.  Influenza virions can be spherical, 
elliptical, filamentous or irregular in shape and range from 80-120 nm in diameter, with a length 
of up to 20 µm in the case of filamentous particles. Cell culture and egg produced influenza 
particles are usually spherical or elliptical in shape, while clinical isolates tend to be filamentous 
(Noda, 2011).  
 
 
 
 
 
5 
 
Figure 1.1: Diagram of the structure of influenza virus (Racaniello, 2009) 
 
1.3 Infection Cycle 
 
The influenza life cycle can be divided into several stages, as shown in Figure 1.2; entry to the 
host cell, entry of viral genome into the nucleus, transcription and replication; export of the 
genome from the nucleus, and assembly and budding of the viral particle at the host plasma 
membrane (Samji, 2009).  
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Figure 1.2: Influenza life cycle (Neumann, Noda, & Kawaoka, 2009) 
Influenza virus enters host cells via the attachment of HA to sialic acid receptors located on the 
cells’ surface. HA forms as a trimer and each individual HA molecule consists of 2 subunits, 
HA1 and HA2, which exist in the precursor form HA0. Subunits HA1 and HA2 are linked by 
disulfide bonds that are cleaved by different serine proteases depending on the strain (trypsin 
cleaves H1 and futin cleaves H5, for example). To initiate infection, HA1 binds to sialic acid 
receptors on the host cell membrane followed by entry via receptor-mediated endocytosis in an 
endosome. Upon entry into the cell, the virus must shed its envelope to release its genome to 
begin producing new virions. Once inside the endosome, the acidic environment works by 
triggering a conformational change in HA0 that exposes the fusion peptide of HA2, which fuses 
the viral envelope with the endosomal membrane. Additionally, the acidic environment opens the 
M2 ion channel that acidifies the viral core and helps to release viral RNA. Once the viral 
genomic material is free it is able to enter the nucleus to begin transcription of viral proteins and 
the replication cycle using both its own and the host’s cell machinery (Samji, 2009). After 
replication the nucelocapsids are exported out of the nucleus by binding to M1 and NP (Acheson, 
2007) where they are incorporated into the viral particle. Mature virions then bud out of the cell 
via the plasma membrane. At this point, the particles may bind back to the cell via sialic acid 
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receptors and HA1, however NA prevents this by cleaving sialic acid from the host cell leaving 
the virion free to move on and further infect susceptible cells.  
1.4 Immune Response 
 
Influenza is a respiratory disease characterized by the onset of high fever, cough, head and 
muscle aches and in rare cases can cause viral pneumonia (Taubenberger, Jeffery K., Morens, 
2008). The virus is transmitted person to person by either direct contact or through aerosols 
spread by coughing or sneezing and replicates in both the upper and lower respiratory tract. Once 
infected with influenza the immune system responds in two ways; the first line of defense is the 
innate immune response, which secrets interferon molecules that interact with healthy cells to 
turn them into an infection resistant state. This helps slow the spread of infection and give the 
immune system a chance to destroy the virus. The innate immune system also induces cytotoxic 
T-cells that destroy infected cells before they have the chance to release mature virions 
(Hancioglu, Swigon, & Clermont, 2007). The second line of defense is an adaptive immune 
response where specific antibodies produced work by attacking the virus itself. Anti-HA 
antibodies prevent infection by either targeting HA1, which blocks the virus from attaching to the 
cell or HA2, which stops membrane fusion once taken up by an endosome. Anti-NA antibodies 
prevent NA from cleaving sialic acid thereby preventing further infection by arresting viral 
release (Chun, Li, Van Domselaar, & Al., 2008).  
Recovery from acute symptoms occurs after 7-10 days, however the infected person can be 
fatigued for up to weeks after infection, especially older people (65+). Due to the fact that 
symptoms occur 2 or 3 days after infection, the acquired immunity that occurs after the first week 
cannot prevent respiratory problems that could develop during this time, requiring advanced 
immunity from vaccines to prevent the complications and spread of the disease (Hancioglu et al., 
2007).  
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Chapter 2: Influenza Vaccines 
 
2.1 Current Influenza Vaccine  
 
Due to the fast mutation rate of influenza, the WHO has put an epidemiological surveillance 
system in place to try to predict the emerging strains for each upcoming flu season in both the 
northern and southern hemispheres. Once the strains that are predicted to be the most common 
for each flu season have been identified, vaccine manufacturers take approximately 6 months to 
produce their vaccines and supply them to health care providers (Gerdil, 2003). Currently, two 
influenza A (H1N1 and H3N2) and one B strains are included in each vaccine dose. Before 
production, a seed stock for each emerging influenza A strain is made by genetic re-assortment 
with a backbone strain such as A/H1N1/Puerto Rico/8/1934 (A/PR8/34) or an A/PR8/34-like 
strain. This is done because A/PR8/34 is a well characterized strain that grows to high titers in 
embryonated hen’s eggs, increasing the yield from potentially low titer wild type strains (Gerdil, 
2003). Once the seed stocks are produced, bulk vaccine production can begin. Whole virus is 
grown in the allantoic cavity of embryonated hen’s eggs, harvested and chemically deactivated 
(with formalin or β-propiolactone), purified by ultracentrifugation and finally split chemically. 
Prior to 2001, both inactivated whole and split vaccines were on the market, but due to increased 
side effects from the inactivated whole vaccine, such as fever and reaction at the injection site, it 
was discontinued (National Network For Immunization Information, 2010). There is also a cold-
temperature attenuated nasal spray vaccine (FluMist, Medimmune) available. The drawbacks of 
the egg based production system include the relatively long 6-month period from strain 
identification to validation and the lack of scalability, where approximately one egg produces one 
vaccine dose. Additionally, avian influenza strains, such as the H5N1, cannot be produced in 
eggs due to its pathogenicity, which is a significant problem considering the potential emergence 
of a pandemic avian strain (Gerdil, 2003). Moreover, vaccines produced in eggs cannot be given 
to persons allergic to eggs, limiting their use.  
2.2 Cell Culture Based Vaccines 
 
To overcome the challenges associated with egg based production of influenza vaccines, cell 
culture alternatives have been proposed. Cell culture processes have several advantages over egg 
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based production such as a superior potential for scale-up, higher initial purity and the absence of 
potential allergens that exist in the egg-based system (Feng, Jiao, Qi, Fan, & Liao, 2010). 
However, anticipated bottlenecks of these systems are purification schemes, especially for 
recombinant VLP systems where it is difficult to purify contaminants that are of similar shape 
and size (i.e baculovirus, system vesicles). Many steps may be involved in order to assure the 
VLPs are free of any contaminants, making this step slower than actual cell culture production. 
The major limitation with this system is higher associated costs, however, their potential still 
remains and both whole virus split and recombinant subunits vaccines have been produced in cell 
culture and will be discussed in the following section.  
2.2.1 Whole Virus  
 
Many mammalian cell lines have been used as a production platform for influenza vaccines. They 
include Madin Darby Canine Kidney (MDCK) cells (Voeten et al., 1999), African Green Monkey 
Kidney Cells (Vero) (Kistner et al., 1998), Human Embryonic Retinal Cells (Per.C6) (Pau et al., 
2001), Human Embryonic Kidney (HEK 293) cells (Le Ru et al., 2010), Human Amniocyte CAP 
(Genzel et al., 2013), Duck AGE1.CR (Jordan et al., 2009; Lohr et al., 2009) and Duck EB66 
(Mehtali, Champion-Arnaud, & Arnaud, 2006). Generally, the MDCK cells are favored for 
influenza virus production because they can produce influenza titers similar to those of eggs, 
however they grow in adherence and require serum-containing media, which limits the scalability 
of this system and requires the use of undesirable and unspecified amounts of animal products 
(Le Ru et al., 2010). In 2012, the first seasonal trivalent inactivated split influenza vaccine made 
in cell culture from MDCK suspension cells, Flucelvax by Novartis, was approved by the FDA 
(FDA, 2012), showing the promise of cell culture based productions. The advantage of cell 
culture derived influenza vaccines over egg-based production is their fast response time and 
scalability, which is important if a pandemic strain was to emerge. However, there are some 
drawbacks, such as high cost, potential of lower yields with some cell types and the possibility of 
producing adventitious agents (Patriarca, 2007). Recombinant strategies to produce subunit 
vaccines which contain no dangerous infectious material, are another potential solution to these 
underlying problems of influenza vaccine production (Cox & Hollister, 2009; Haynes, 2009).  
2.2.2 Recombinant Subunit Vaccines 
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Subunit vaccines consist of the purified influenza viral antigen HA. One method to produce 
subunit vaccines is by production of the target antigens with recombinant technology. The 
different kinds of recombinant influenza vaccines have been outlined in a review by Sedova et al 
( 2012). Recently, an insect cell produced season subunit influenza vaccine, Flublok by Protein 
Sciences Corporation has been approved by the FDA (FDA, 2013). Influenza virus-like particles 
can be considered as recombinant subunit vaccine candidates. They are non-infectious and non-
replicating particles displaying intact and biochemically active antigens, HA and/or NA that do 
not contain genetic material (Haynes, 2009). Additionally, influenza VLPs can be constructed 
with one or both of the two matrix proteins, M1 and M2 (Kang et al., 2009; Pushko et al., 2005; 
Wu et al., 2010).   
Thus far, different production platforms have been studied for influenza VLPs. They vary 
according to the viral strain produced, the type of gene delivery used and the host-cell expression 
system. Currently, influenza VLPs have been produced in mammalian, insect and plant cell 
platforms using a variety of vectors and gene delivery techniques (D’Aoust et al., 2010; Krammer, 
Nakowitsch, et al., 2010; Tang, Lu, & Ross, 2011). The most extensive amount of VLP studies 
thus far have been done in insect cells with the baculovirus expression vector system (BEVS) 
(Bright et al., 2007; Krammer, Nakowitsch, et al., 2010; Pushko et al., 2005; Quan, Huang, 
Compans, & Kang, 2007). Mammalian cells have also been used to produce VLPs with 
transfection/transduction (B. J. Chen, Leser, Morita, & Lamb, 2007; Tang et al., 2011), vaccinia 
virus (Schmeisser et al., 2012) and murine leukemia virus (MLV) (Szécsi et al., 2006) based 
systems in HEK 293T, HeLa and COS-1 cells. Finally, H5 and H1 VLPs containing HA have 
been successfully produced in plant cells using the Agrobacterium infiltration-based transient 
expression in the tobacco plant, Nicotiana benthamiana (D’Aoust et al., 2008). This system is 
currently in clinical trials (Landry et al., 2010) and has shown to be very promising in terms of 
speed and manufacturing costs (D’Aoust et al., 2010).  
Considering that recombinant vaccines are biosafety level 1 (BSL-1), and whole virus production 
is BSL2, recombinant methods are more attractive from a safety point of view. If recombinant 
vaccines can produce equivalent material (i.e highly efficacious antigens), compared to those 
produced from whole virus production at similar costs, then they the most promising platform for 
future vaccines.   
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Chapter 3: VLP Production in Cell Culture 
 
3.1 General VLP Production and Purification Scheme 
 
Shown below in Figure 3.1 is the general procedure for influenza VLP production and 
purification that will be described in this section. Generally, clarification by centrifugation is has 
been the gold standard for this step. However, a more scalable method using membrane filtration 
in either dead-end or tangential flow modes are also an option (Vicente, Roldão, Peixoto, 
Carrondo, & Alves, 2011). To concentrate and purify VLPs, ultracentrifugation schemes have 
been generally used, however chromatography methods have been explored, as they are generally 
more scalable than ultracentrifugation and easier to use in a manufacturing environment. Bind 
and elute mode is good because is has the ability to purify and concentrate the product, however 
purification in flow-through mode has also been used for influenza VLP purification (GE 
Healthcare, 2012; Vicente et al., 2011). 
             
Figure 3.1: General steps for influenza VLP production and purification 
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3.2 Upstream 
 
3.2.1    Baculovirus Expression Vector System (BEVS) 
 
The BEVS is a well-established system for recombinant protein expression and has been used in 
industry for over 20 years (Jarvis, 2009). Autographa californica nuclear polyhedrosis virus 
(AcNPV) is the most well-known and used baculovirus (BV) in the biotechnology industry. It 
infects the alfalfa looper (A.californica), the fall armyworm (Spodoptera frugiperda) and also the 
American cabbage looper (Trichoplusia ni). BV is a double-stranded DNA based enveloped virus 
that buds from the cell’s plasma membrane to produce rod shaped particles 40-50 nm in diameter 
and 200-400 nm in length (Gerster et al., 2013). The two cell lines most widely used are Sf9 (S. 
frugiperda) and BTI-TN5B1-4 (T.ni, commercially known as High Five™) and have been used 
extensively for the production of both intracellular and secreted proteins (Krammer & Grabherr, 
2010). The most commonly used promoter is the strong polyhedron (polh) promoter, which 
produces the polyhedron protein that coats the occlusion derived (OD) particle that is produced 
during insect infection. In biotechnology applications, only the budded virion (BV) is used, 
leaving the polyhedron promoter open to express a gene of interest (Jarvis, 2009). The BEVS has 
the ability to operate at high cell densities up to 14.0 x 106 cells/ml and uses less expensive media 
compared to mammalian cell culture, allowing for higher yields at lower cost (Bernal, Carinhas, 
Yokomizo, Carrondo, & Alves, 2009; Elias, Zeiser, Bédard, & Kamen, 2000). Insect cell 
glycosylation differs from mammalian glycosylation in the N-glycans, producing 
paucimannosidic and oligomannosidic acid instead of sialic/galactose acids (Krammer & 
Grabherr, 2010). Many commercial by suppliers such as BD Biosciences and Invitrogen produce 
kits to construct baculovirus vectors yielding a gene of interest and a working viral stock can be 
created as fast as one month. The BEVS system has been the most widely used production 
platform explored thus far for influenza VLP production. However, this system suffers from 
contamination with BV particles as they also bud from the cell into the supernatant. During the 
budding process, BV has the ability to take up influenza glycoproteins into its membrane, 
complicating VLP quantification, characterization and purification (Tang, Lu, & Ross, 2010). 
Baculovirus also has the ability to transduce a variety of cell types such as human, rodent, 
porcine, rabbit, bovine, fish and avian (C.-Y. Chen, Lin, Chen, & Hu, 2011). Once inside the cell, 
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genes of interest can be expressed as long as they are under control of an appropriate promoter 
(i.e cytomegalovirus intermediate-early CMV or hsp70) (Kost, Condreay, & Jarvis, 2005). 
Baculovirus is unable to replicate or integrate its DNA into host human cells, making it an ideal 
system for gene delivery (C.-Y. Chen et al., 2011). The addition of butyric acid, which causes 
hyperacetylation of histones, leads to enhanced transcription, and an increased amount of protein 
production (Kruh & Saint, 1982). Another additive that performs the same function as butyric 
acid is valproic acid (Backliwal et al., 2008). The baculovirus-mammalian cell transduction 
system (Bacmam) has been applied for influenza VLP production by Tang et al (2011) in 
adherent HEK 293T cells to try and avoid the recurring problem of baculovirus contamination in 
VLP production with Sf9 cells (Margine, Martinez-Gil, Chou, & Krammer, 2012). Tang et al 
showed that transduction produced equivalent amounts of influenza VLPs compared to liposome 
transfection with analysis with western blot and fluorescence.  Advantages of producing 
influenza VLPs in mammalian cells include obtaining human-like glycosylation that cannot be 
obtained in insect cells. De Vries et al showed that recombinant HA with complex mammalian 
glycan structures were able to elicit higher HI antibody titers in chicken and mice compared to 
recombinant HA produced in insect cells with less complex glycans (2012). However due to the 
contamination and purification problems encountered for VLP production in insect cells, a direct 
comparison on the immune response between purified influenza VLPs with insect or human-like 
glycosylation patterns have not yet been studied.  
3.2.2 Cell Culture Processes 
 
VLP production in insect and mammalian cells has been relatively simple, at small scales (i.e – 
up to 200 ml) usually in shake or T flasks. Generally, DNA is introduced to insect cells through 
infection with baculovirus, or to mammalian cells by plasmid transfection or transduction with 
baculovirus. They are then left to incubate for 48-72 hours after which the supernatant is 
harvested on the assumption that VLPs bud out of the cell. For VLP production in HEK 293 cells 
the addition of butyric acid and valproic acid at concentrations in the media ranging from 0.25-5 
mM were explored. Studies on scale up from shake flask to bioreactor have not been reported for 
influenza VLP production. In the literature, the methods focus on how VLPs were produced, but 
most of the time quantitative aspects deal with characterizing final purified products and 
immunological challenge responses. One of the major limiting factors for the development of 
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production processes for influenza VLPs is the lack of quantification methods suitable during all 
stages of process development. 
3.3  Downstream Processing 
 
3.3.1 Purification 
 
After the culture supernatant has been harvested, influenza VLPs are purified in downstream 
processing steps (DSP). The first step involves slow centrifugation (300 x g) to remove cells and 
any other large debris. Next, the clarified supernatant needs to be concentrated, which is usually 
done with ultracentrifugation with or without a sucrose cushion of 25-30%. In a protein 
purification scheme, proteins are usually concentrated with affinity chromatography (i.e - with 
the use of a histidine tag). Due to their large size, VLPs are usually concentrated by 
ultracentrifugation, however in an affinity-based scheme specific to VLP proteins (HA), 
concentration could also be achieved. For ultracentrifugation concentration, larger particles (such 
as VLPs) are able to pass through the sucrose cushion and pellet at the bottom of the bottle based 
on their density. Free proteins will pellet at a slower rate, therefore this step also partially purifies 
the VLPs from smaller contaminants such as free cellular proteins that were not removed during 
slow centrifugation. Further purification is usually done with ultracentrifugation steps, but can 
also be accomplished using chromatography based methods, outlined in the next sections.  
3.3.1.1 Density Gradient Ultracentrifugation 
 
Currently, most researchers use ultracentrifugation steps to purify influenza VLPs (Bright et al., 
2007; Latham & Galarza, 2001; Margine et al., 2012; Tang et al., 2011). This is done either with 
the use of a sucrose or iodixanol gradient ultracentrifugation. This step works by layering 
different concentrations of sucrose (20-30-40-50-60%) and then collecting each concentration for 
analysis after centrifugation. Each concentration of sucrose has a different density, and the VLPs 
migrate to the zone with the same density, purifying them from other debris that could not be 
removed in previous steps. Iodixanol is a self-forming density gradient medium used in place of 
sucrose to complete purification by density gradient ultracentrifugation (Van Veldhoven, 
Baumgart, & Mannaerts, 1996).  
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3.3.1.2 Chromatography 
 
Chromatography can also be used to purify influenza VLPs. To date, most of the purification for 
influenza VLPs has been done with ultracentrifugation using sucrose or iodixanol gradients. 
These techniques are well established and convenient to use for small-scale production, 
especially when chromatography-based purification has not yet been fully developed and 
explored. However, ultracentrifugation is quite labour intensive and has poor scalability (Vicente 
et al., 2011). Therefore, as the influenza VLP field grows, there have been recent reports of 
influenza VLP purification using chromatography steps (D’Aoust et al., 2010; GE_Healthcare, 
2012). These include size exclusion chromatography, and ion-exchange protocols.  
3.4 Quantification 
 
Quantification methods for influenza VLP and virus can be categorized into two general classes. 
The first provides information on antigen quantity, in the amount of HA (SRID, HA assay) or of 
enzymatic NA activity, but currently there is no commercial vaccine with quantified NA. The 
other quantification type gives information on the morphology and concentration of VLPs. 
Techniques used for particle quantification of viruses (qPCR, TCID50) are not applicable for 
VLPs due to their lack of genome and infectivity. Currently, the only method available to 
quantify total VLPs is counting by electron microscopy. There is a relationship between the HA 
assay and the number of influenza particles that could be used to estimate VLP total particle titers 
but this correlation cannot be used with confidence as outlined by Thompson et al (2013). In the 
following sections, methods used to quantify and characterize influenza VLPs are described in 
greater detail. 
3.4.1 Hemagglutination (HA) assay  
 
The hemagglutination assay was the first method proposed to quantify the influenza virus based 
on its agglutination property (Hirst, 1942). This method has remained largely unchanged since it 
was first developed and has been used for the quantification of HA activity in viral preparations 
(Kalbfuss, Knöchlein, Kröber, & Reichl, 2008; Petiot et al., 2011). Although this assay is not 
considered a standard method by health authorities, many production and purification yields of 
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influenza VLPs use this technique (Pushko et al., 2005, 2011; Quan et al., 2007; Schmeisser et al., 
2012). The basis of agglutination is HA’s ability to bind sialic acid on erythrocytes (RBC). This 
is crucial for influenza virus because the virus must bind to sialic acid to enter the cell and begin 
the infection cycle (Samji, 2009). This point is not significant for VLPs, as they are non-
infectious, but their ability to bind sialic acid shows that HA is in the correct conformation and 
active. To complete the assay, serial dilutions of VLPs are made which RBCs are added. Based 
on the last well that has hemagglutination, which corresponds to the minimal amount of virus 
particles that cause complete hemagglutination, the titer of HA in terms of HA units (HAU) can 
be calculated.  
3.4.2 Electron Microscopy   
 
Historically, electron microscopy (EM) has been used for virus observation and influenza whole 
virus quantification (Isaacs & Donald, 1955). EM has also been used to verify the presence and to 
characterize influenza VLPs in terms of morphology and size (Krammer, Nakowitsch, et al., 
2010; Pushko et al., 2005; Schmeisser et al., 2012). In order to quantify, negative stain electron 
microscopy (NSEM) is used where samples are prepared, fixed on a grid, and stained for 
enhanced visualization. Particles are counted within the gridlines and compared to a quantified 
standard of silicon beads that are also present on the grid.  
3.4.3 Single Radial Immunodiffusion (SRID) 
 
Current human influenza vaccine doses are determined from the single radial immunodiffusion 
(SRID) assay, the only validated potency test used for the quantification of HA protein in 
trivalent influenza vaccines (Pincus, Boddapati, Li, Sadowski, & Pincus, 2010). This assay 
measures the radial diffusion of HA in an agarose gel containing specific antibodies. The 
diameter of the ring is then compared against quantified standards to determine its amount. In 
contrast to the hemagglutination assay, this method measures the HA content expressed in µg of 
HA/ml and has a limit of detection of approximately 3-5 µg/ml (Schild, Wood, & Newman, 
1975). This method is widely used for VLP characterization (Bright et al., 2007; Easterbrook et 
al., 2012; Landry et al., 2010; López-Macías et al., 2011; Mahmood et al., 2008; Pushko et al., 
2011).  
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3.4.4 Western Blot 
 
Western blot is used to verify the presence of the proteins that make up the VLPs. This is the only 
method available that can identify the presence of influenza matrix proteins. Western blot is a 
well-established method, simple to complete and can also give indication of the amount of 
contaminating proteins with the appearance of non-specific bands. However, this method is really 
only suited for purified or semi-purified samples, making analysis complicated with in-process 
samples. 
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Chapter 4: Research Objectives 
 
Most of the studies thus far have focused on the proof of concept that VLPs can be produced and 
on the immunogenicity of influenza VLPs to support their candidacy as potential vaccines 
(Latham & Galarza, 2001; Pushko et al., 2005). Bright et al (2007) showed that influenza VLPs 
are able to elicit a broader immune response than inactivated whole virus inactivated or 
recombinant hemagglutinin vaccines; and Mahmood et al (2008) showed that an H5N1 vaccine 
induced protection in ferrets against a lethal injection from H5N1 virus. Additionally, VLPs have 
been used as a model to gain insight into the minimal requirements for influenza virus budding 
(B. J. Chen et al., 2007). With all the work done in this field to date, little attention has been paid 
to the bioprocessing aspect of VLP production. However, studies of this nature are starting to 
surface, Krammer et al. completed an investigation on the comparison of Sf9 and High Five cells 
for VLP production and found that High Five cells were more productive with less contamination 
from baculovirus (Krammer, Schinko, et al., 2010). This result agrees with Aucoin et al, however 
Sf9 cells have the ability to operate at high cell densities, which could compensate for the higher 
productivity of High Five at lower densities (Aucoin, Mena, & Kamen, 2010). Additionally, a 
study by Tang et al. (2011) highlighted a potential solution to contaminating baculovirus with 
production of VLPs in mammalian cells by Bacmam transduction (Tang et al., 2011). Finally, 
Vincente et al (Vicente et al., 2011) outlined the steps and potential methods to complete large 
scale production and purification of VLP vaccines, however the focus was not specifically on 
influenza VLPs but VLPs in general.  
In line with the theme of studying influenza VLPs from a bioprocressing point of view, this study 
aims to characterize quantitatively two of the production platforms tried thus far for VLP 
production, and to critically analyze the pros and cons of each system. 
Objective #1: Produce influenza VLPs with the insect cell-baculovirus and mammalian cell-
bacmam systems 
• Determine the best production condition for each system with the use of western blot, 
GFP fluorescence and HA assay 
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Objective #2: Investigate VLP production from the insect cell-baculovirus production and 
mammalian cell-bacmam from a bioprocessing standpoint 
• Determine production values for each platform in terms of total VLPs produced per 
production volume, µg HA/ml and HAU/ml from both of their best production conditions 
• Quantify the amount of contaminant baculovirus from the Sf9-baculovirus production 
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Chapter 5: Methods 
 
5.1   Construct design 
 
The DNA sequence of H1N1 A/Puerto Rico/8/1934 HA (AB671289.1), NA (AB671290.1) and 
M1 (CY033578.1) were obtained from NCBI’s influenza database. Sequences were sent to 
BioBasic (Markham, Canada) for construction in the vector pUC with XbaI and BglII restrictions 
sites on the C- and N-terminal of each gene. Each vector was then amplified in E.Coli and 
purified using the Qiagen miniprep system (Venlo, Netherlands). Each vector was digested with 
XbaI and BglII restriction enzymes from New England Biolabs (Ipswich, USA) and HA, NA and 
M1 inserts isolated using agarose gel electrophoresis and purified.  To make baculoviruses, the 
BD bioscience (Franklin Lakes, USA) BaculoGold™ system was used. pVL1393 vectors were 
amplified in E.Coli and purified using Qiagen’s miniprep system and further digested in the 
multiple cloning site with restriction enzymes XbaI and BglII. The remaining vector was then 
isolated by separation with agarose gel electrophoresis and purified. pVL1393 and the HA, NA 
and M1 inserts were ligated with T4 Ligase (New England Biolabs), amplified and purified using 
Qiagen’s maxiprep kit to yield pVL1393-HA, pVL1393-NA and pVL1393-M1. All three genes 
are under the control of the polyhedron promoter (polh) 
The construct used for HEK 293 was kindly donated by Dr. Ted Ross at the University of 
Pittsburg. Its construction can be found in Tang et al (2011). Briefly, it was made using the Bac-
to-Bac baculovirus construction system (Carlsbad, USA). Each influenza protein, HA, NA and 
M1 were under CMV control to create a baculovirus that is able to express proteins in 
mammalian cells (BacMam). Additionally, green fluorescent protein (GFP) was coded under its 
own CMV promoter to use as a marker. Finally, to promote transduction, baculovirus was 
pseudotyped with VSVG under polyhedron control.  
5.2   Cells and Medium 
 
The HEK 293SF (referred to as HEK 293 in this document) cell line used for VLP production 
was previously adapted to suspension and serum-free culture (Côté, Garnier, Massie, & Kamen, 
1998). Working cell banks were made from a vial of the master cell bank, which was developed 
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under Good Manufacturing Practices (cGMP). HEK 293 cells were sub-cultured every three days 
and discarded after 2 months, when a new aliquot from the working bank was thawed for use. 
HEK 293 cells were grown at 37 °C and 5% CO2, in animal and serum free SFM4Transfx 
293TM (HyQ) medium (HyClone, Waltham, MA, USA) with shaking at 120 rpm. Cells were 
counted using a hemacytometer or the Cedex Cell Counter (Innovatis Roche Applied Science, 
Penzberg, Germany) when they were subcultured. 
Insect Spodoptera frugiperda (Sf9) cells were maintained in serum free Sf900 II media (GIBCO, 
Burlington, ON, Cananda), in shake flasks at 27 °C with shaking at 110 rpm. Cells were sub-
cultured twice each week and maintained for 2-3 months before discarding for a fresh vial from 
the working sock. Cell density was measured using the Cedex Cell Counter (Innovatis Roche 
Applied Science, Penzberg, Germany). 
5.3  Viral stock production 
 
5.3.1 Amplification 
 
To make recombinant baculoviruses, pVL1393-HA, pVL1393-NA and pVL1393-M1 were all 
mixed with BaculoGold™ baculovirus linearized DNA at a ratio of 4:1 to give a total of 2 µg 
DNA. Sf9 cells at 1x106 cells/ml were transfected with Polyethylenimine (PEI) and the DNA mix 
at a ratio of 2.5:1 and left to incubate for 5 days at 27 °C.  Each supernatant was harvested and 2 
ml of this stock (called P0) was used to infect 200 ml of Sf9 cells at 2.6x106 cells/ml. Cell density, 
viability and cell diameter for each amplification were measured every 24 hours with a Cedex 
Cell counter from Roche Diagnostics (Basel Switzerland). Culture supernatants were harvested 
after 72 hours at a viability of 60%, 56%, and 39% for P1-BacHA, P1-BacNA, P1-BacM1, 
respectively. Each was filtered with a 0.22 µm filter and stored in the dark at 4°C. Protein 
expression was verified with western blot analysis and each virus was titered for total and 
infectious particles.  
The bacmam virus was amplified in a similar way except it was constructed in the Bac-to-Bac 
system. Sf9 cells were seeded at 0.5x106 cells/ml and PEI and bacmid DNA were mixed at a ratio 
of 2.5:1 and left to incubate at 27°C for 5 days. Supernatant was harvested and 1 ml was used to 
infect 100 ml of Sf9 cells at 2.4x106 cells/ml.   
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5.3.2 Working Stock Production: 3 L Bioreactor 
 
A second round of amplification was done in an A3-3L bioreactor Chemap SG type bioreactor 
(Mannedorf, Switzerland) to create a working stock (P2) for each virus. The working volume was 
2.7 to 2.8 L and the bioreactor was equipped with two sets of 45º pitched-blade impellers with a 
ratio of impeller to bioreactor diameter of 0.5 and three top-mounted vertical baffles. The 
temperature was maintained at 27ºC by a water jacket. The partial pressure of oxygen (pO2) was 
measured with a polarographic oxygen electrode (Mettler-Toledo, Urdorf, Switzerland) and 
dissolved oxygen (DO) was maintained at 40% by surface aeration with a gas mixture of nitrogen 
and oxygen at a total flow rate of 300 cm3/minute (ccm). The stirring speed was maintained with 
the chemap control unit at 110 rpm. The pH was measured with a gel-filled electrode (Mettler-
Toledo) and culture capacitance was measured with a Biomass Monitor 220 (Aber Instruments, 
Aberystwyth, UK). The bioreactors were seeded at 0.5x106 cells/ml in Sf900 II media and cells 
were allowed to grow until reaching a density of approximately 4-5×106 cells/ml, after which 
they were diluted with fresh Sf900 II media to 2-2.5x106 cells/ml. Cultures were then infected at 
this concentration by direct addition of baculovirus virus (MOI = 0.1-2) to the culture. Samples 
were taken twice a day to be counted and measure their viability and average cell diameter. 
5.4   Viral Stock Titering 
 
5.4.1 Flow Cytometry: Total Particle Analysis 
 
All P1 and P2 baculovirus stocks were titered for total viral particles using flow cytometry (FC). 
First, stocks were diluted 100 x with 1x PBS buffer to create the working stock. 100 µl of the 
working stock virus was added to 850 µl 1x PBS, 20 µl 5% paraformaldehyde and incubated at 
4°C for 1 hour to complete fixation of viral particles.  Fixed samples were frozen in a mixture of 
dry ice and ethanol for 10 minutes, and then thawed in a water bath. Next, the fixed viral particles 
were permeabilized with the addition of 10 µl of 10% Triton-X for 5 minutes. After 
permeabilization, samples were stained with 20 µl of 5x10-3 diluted stock of Invitrogen SYBR 
Green I (Carlsbad, USA). Samples were heated in the dark in a 80°C water bath for 10 minutes, 
and cooled at room temperature for 5 minutes, before being transferred to polystyrene tubes for 
analysis.  Samples were analyzed with a flow cytometer (EPICS XL-MCL, discriminator: green, 
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voltage and gain of multiplier: 650 V and 2, threshold: 0 and acquisition time: 30 sec) and 
compared against the flowset standard that contained 1x106 particles/ml. Flow cytometer profiles 
looked similar for each virus with minimal amount of aggregation. Total particle concentration 
was calculated as shown in Appendix 1a. 
5.4.2 Easy Titer: Infectious Particles Analysis 
 
All viral stocks were titered for infectivity using Sf9 ET/GFP (Easy Titer) cells with a method 
developed by Hopkings et al (2009). This method was made to replace the TCID50 assay for 
infectious particles and is based on GFP expression from Sf9 ET/GFP cells once infected with 
baculovirus. GFP is introduced under polyhedron control, which is turned on during the early 
replication cycle of the virus. Virus stocks were diluted 1:500 using Thermoscientific SFX 
HyClone insect cell medium (Waltham, USA) as a diluent. Plates were filled with 100 µl of 
diluent in rows A-H columns 2-10 and then 125 µl of diluted virus stock in rows A-H, column 1. 
The virus was serially diluted 1:5 in each column from 1-9 and column 10 was left blank as a 
control.  The Sf9 ET/GFP cells were seeded into each well with 100 µl of working stock for a 
final cell concentration of 7.4x104 cells/well using a multichannel pipette.  Plates were placed in a 
plastic storage container with a damp towel to maintain moisture and incubated for 5 days at 
27 °C. Then TCID50 values were determined by scoring GFP positive wells for each virus stock. 
Based on GFP positive wells, the infectious titer was calculated (Appendix 1b). Table 5.1 shows 
the infectious and total particle titers of each viral stock calculated using this method and the FC 
method previously described. 
Table 5.1: Total and infectious titers of each virus stock made. 
Virus Stock Total Virus 
Particles/ml 
Infectious Virus 
Particles/ml 
Total Particles: 
Infectious Particles 
P1 HA Baculovirus polh 5.79x109 9.22x108 6.28 
 
P2 HA Baculovirus polh 6.46x108 1.02x108 6.33 
P1 NA Baculovirus polh 4.74x108 1.62x108 2.93 
P2 NA Baculovirus polh 1.92x109 1.15x108 16.7 
P1 M1 Baculovirus polh 1.21x109 3.18x108 3.81 
P2 M1 Baculovirus polh 3.51x109 1.34x108 26.2 
P1 HA+NA+M1 Bacmam 
CMV 
2.88x109 5.83x107 49.4 
P2 HA+NA+M1 Bacmam 
CMV 
3.79x109 1.21x109 3.1 
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In order to calculate the multiplicity of infection (MOI) for VLP production, the infectious titer 
must be known. MOI represents the number of infectious virus particles (IVP) added per cell in 
culture. It is calculated with the following equation 
𝑀𝑂𝐼 =    𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑢𝑠  𝑇𝑖𝑡𝑒𝑟   𝐼𝑉𝑃𝑚𝐿 ×  𝑉𝑖𝑟𝑢𝑠  𝑉𝑜𝑙𝑢𝑚𝑒  (𝑚𝐿)𝐶𝑒𝑙𝑙  𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛   𝐶𝑒𝑙𝑙𝑠𝑚𝐿 ×𝑇𝑜𝑡𝑎𝑙  𝑉𝑜𝑙𝑢𝑚𝑒  (𝑚𝐿) 
 
5.5 VLP Production 
5.5.1 Mammalian Platform 
 
Cells were transduced with the P2 working stock at a density of 1.0-2.0x106 cells/ml with MOIs 
ranging from 1-200 at 37°C. Twice a day to every 24 hours, cell density, viability and average 
cell diameter were measured using the Cedex Cell Counter (Innovatis Roche Applied Science, 
Penzberg, Germany).  
5.5.1.1 µ-24 MOI and Additive Study 
 
MOI and additive runs were completed in a 6 ml µ-24 microbioreactor (Pall, New York, USA) 
with a 5 ml working volume. 48 hours before transduction, 1 ml of media was added to each well 
to calibrate the pH and temperature probes. 24 hours prior to transduction, each well was seeded 
with cells at a concentration of 0.5-0.75x106 cells/ml so they could be transduced the following 
day between 1.0-1.5x106 cells/ml. DO was controlled at 40% with the addition of oxygen and 
inert gas, pH was monitored and controlled at 7.2 with CO2 addition, and the cassette was mixed 
by shaking at 500 rpm.  Baculovirus was added to give MOIs ranging between 1-200 followed by 
the addition of butyric acid or valproic acid for a final working concentration of 0.25-5 mM. Cell 
density was measured 24, 30 and 48 hpt using a cedex cell couter or hemacytometer. Cells were 
harvested 48-72 hours post transduction and cells were analyzed for GFP expression and 
influenza protein expression by western blot.  
5.5.1.2 Shake Flask Production 
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All other runs were completed in shake flasks (0.250-2 L with 60-400 ml working volume, 
respectively). Cells were transduced at 1.0-2.0x106 cells/ml with baculovirus at an MOI of 60, 
followed by addition of butyric acid for a final concentration of 5 mM. After 48 or 72 hours the 
cells were clarified by slow centrifugation at 300 x g for 5-10 minutes. The supernatant was 
concentrated via sucrose cushion ultracentrifugation and analyzed by western blot, HA assay, 
NSEM and SRID. SCC-VLPs were further purified using iodixanol density gradient 
ultracentrifugation.   
5.5.2 Insect Platform 
 
VLP productions were completed in shake flasks (0.250-2 L flasks with 60-400 ml working 
volume, respectively). Cells were infected with P2 working stocks at a density of 2.0-2.5x106 
cells/ml with a total MOI of 0.3-2.1 at 27°C. Every 24 hours, cell density, viability and average 
cell diameter were determined using the Cedex Cell Counter (Innovatis Roche Applied Science, 
Penzberg, Germany). Cells were harvested after the viability started to decline but before it 
reached 50%, preferably around 70%. Upon harvest, cells were separated from the supernatant 
with slow centrifugation at 300 x g for 5-10 minutes. The supernatant was concentrated via 
sucrose cushion ultracentrifugation and analyzed by western blot, HA assay, NSEM and SRID. 
Further purification was achieved using density gradient ultracentrifugation.  
5.5.3 Cell Pellet Analysis 
 
To explore the possibility of VLPs trapped within or attached to Sf9 or HEK 293 cells and to 
develop an appropriate method of release, the cell pellet obtained after slow centrifugation was 
re-suspended in a solution of 1x PBS and 10 µg/ml of TPCK-trypsin and slowly shook at 37°C 
for 30 minutes. Cells were pelleted via slow centrifugation and the cell pellet wash was collected 
for analysis by western blot, HA assay and NSEM. To explore the possibility of internally 
budded VLPs, cell pellets were frozen at -80°C and thawed to induce cell lysis and the 
supernatant was removed via centrifugation at 1000 x g for 5 min. The supernatant was analyzed 
using western blot, HA assay and NSEM. 
5.6 VLP Purification by Ultracentrifugation 
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5.6.1 Sucrose Cushion Ultracentrifugation 
 
Concentration by sucrose cushion ultracentrifugation works as to both concentrate and semi-
purify by removing free proteins found in the supernatant. 200 ml of supernatant from VLP 
productions in both Sf9 and HEK 293 cells were loaded into cold 250ml ultracentrifugation 
bottles. If there was not 200 ml of supernatant available, the volume was completed to 200 ml 
using 20 mM Tris-HCl at pH 7.5. The VLP supernatants were under layered with 10% of the 
VLP supernatant volume with 20 mM Tris-HCl 25% sucrose at pH 7.5 (i.e 20 ml 25% sucrose 
solution for 200 ml VLP supernatant). This was spun at a speed of 37 000 x g for 3 hours (Sorvall 
Discovery SE 100 ultracentrifuge, A621 rotor, Thermo Scientific, Waltham, USA) at 4°C. The 
supernatants were then discarded and the remaining VLP pellet was re-suspended in 20 mM Tris-
HCl, 1% sucrose, 2 mM MgCl2 overnight at 4°C to give a total concentration factor of 20-75x. 
Sucrose cushion VLP solutions were then aliquoted and stored at either -80°C, 4°C or subjected 
to further purification by iodixanol density gradient ultracentrifugation.   
5.6.2 Iodixanol Density Gradient Ultracentrifugation 
 
Iodixanol density gradient ultracentrifugation works by separating particles based on their density. 
A 40% w/v working stock was made using 20 g of 60% w/v Optiprep Iodixanol solution (Axis-
Sheild, Oslo, Norway) with 10 g of 60 mM Tris-HCl pH 7.5. A 25.5% working stock was made 
using 19.13 g of the 40% working stock with 10.87 g of 20 mM Tris-HCl pH 7.5. Next, 13 ml of 
the 25.5% working stock and 3.51 ml sucrose cushion purified VLPs were combined and 
subjected to slow mixing to give a final iodixanol concentration of 20% and VLP dilution of 4.7x. 
The VLP-iodixanol solution was then loaded into 13 ml ultracentrifuge tubes, sealed and spun at 
350 000 x g for 6 hours at 4°C (Sorvall Discovery SE 100 ultracentrifuge, 65V13 rotor, Thermo 
Scientific, Waltham, USA). After ultracentrifugation, 1 ml fractions were taken from the bottom 
of the tube and weighed to determine the density and iodixanol concentration in each. Each 
fraction was analyzed by western blot, HA assay and NSEM. 
5.7  VLP Quantification and Detection 
 
5.7.1 Western Blot 
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30 µl of 1.4 M DTT was added to 250 µl SDS-sample buffer from Bio-Rad (Hercules, USA). 
Samples were then added at a ratio 2:1 to the reduced sample buffer and left to equilibrate at 
room temperature for 5 minutes. Samples were boiled at 100 °C for 5 minutes and left to 
equilibrate for 5 minutes at room temperature. Samples were then centrifuged for 30 seconds at 
13 000 x g and loaded into a Bio-Rad mini-protean Tris-Glycine 4-15% electrophoresis gel with 
1x running buffer (25 mM Tris, 192 mM Glycine, 3.5 mM SDS). The gel was run for 40 minutes 
at 200 V and then washed 3 times with Towbin transfer buffer (25 mM Tris, 192 mM Glycine, 
20% Methanol pH 8.3) before being transferred to a nitrocellulose membrane via semi-dry 
western transfer with a Bio-Rad Trans-Blot 3D semi-dry transfer cell for 1 hour at 10 V.  After 
the transfer the membranes were incubated with 5% non-fat milk solution in 0.1% Tween 1x TBS 
pH 7.5 (50 mM Tris, 150 mM NaCl, 0.1% Tween-20) for 1 hour. The membrane was washed 3 
times for 10 minutes with 0.1% Tween TBS pH 7.5 and then incubated with its respective 
antibody at a concentration of 1/1000 overnight at 4 °C. The membranes were washed again 3 
times for 10 minutes with 0.1% Tween TBS pH 7.5 then incubated for 1 hour with 1/1000 
secondary antibodies. Finally, the membranes were washed once again with 0.1% Tween TBS 
pH 7.5 4 times for 10 minutes and then a picture of each was taken with as DS Image Station 
440CF (Kodak, Rochester, USA). 
Table 5.2: List of Antibodies used for western blots 
Antibody Type Manufacturer 
Anti-HA Primary Polyclonal sheep 
serum 
NIBSC, London, United 
Kingdom 
Anti-NA Primary Polyclonal sheep 
serum 
NIBSC, London, United 
Kingdom 
Anti-HA 
 
Primary Monoclonal Mouse Santa Cruz Biotechnology, 
Santa Cruz, USA 
Anti-M1 
 
Primary Monoclonal Mouse AbCam, Cambridge, United 
Kingdom 
Anti-GP64 
 
Primary Monoclonal Mouse eBioscience, San Diego, USA 
Donkey anti-sheep IgG 
 
Secondary HRP Jackson ImmunoResearch, 
West Grove, USA 
Donkey anti-mouse IgG 
 
Secondary HRP Jackson ImmunoResearch, 
West Grove, USA 
5.7.2 Hemagglutinin (HA) Assay 
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The assay was completed in 96 well v-bottom plates. Plates were filled with 100 µl of 1x PBS 
solution in rows A-H, column 2-12. Each sample took up two rows (A and B, C and D, etc) and 
was serially diluted with VLP samples from the supernatant, sucrose cushion and iodixanol 
purifications. Once the wells were serially diluted, 100 µl of red blood cells at a concentration of 
2x107 cells/ml were added to each well in the plate for a final concentration of 1.25%. The plates 
were left in a plastic container for 3 hours to overnight and scored. If hemagglutination of the 
RBCs by the VLPs has occurred, then the solution in the well will be light red and homogenous. 
If hemagglutination did not occur, there will be a cell pellet at the bottom of the well of RBCs, 
referred to as a button. There exists a grey area when reading the plates, based on the size and 
shape of the dot, where some may consider that hemagglutination still partially occurs. Section 
6.4 explains this point further. Calculations to determine HA units/ml can be found in Appendix 
2.  
5.7.3 SRID assay 
 
To a 1% agarose solution in 1x PBS, equilibrated to 50 °C in a water bath, Anti-HA sheep serum 
(NIBSC, London, United Kingdom) was added and mixed. The agarose-antibody mixture was 
cast and left to cool in a Bio-Rad gel-casting module for at least 15 minutes. Once the gel was set, 
4 mm wells were punched into the gel. Purified recombinant A/H1N1/Puerto Rico/8/1934 from 
Protein Sciences Corporation (Meriden, USA) at 30, 20, 15 and 7 µg/ml was used as a standard. 
Treatment with 1% Zwittergent for 15 minutes on a rocker platform was used to help break up 
VLPs or VLP aggregates to allow for better diffusion. 20 µl of each sample was added to its own 
well and left at room temperature for 18-24 hours. The gel was dried using Whatman #3 filter 
paper (Kent, United Kingdom) and paper towels to absorb the liquid. After removing and 
replacing the paper towel 3 times (but keeping the filter paper on top of the gel), the gel was 
placed in a 37°C incubator for 15 minutes before removing the filter paper and continuing the 
incubation until the gel was transparent. The gel was rinsed with deionized water and stained 
with Coomassie Blue R-250 for 15 minutes and distained using a 7.5% acetic acid and 10% 
ethanol solution. The gel was photogrpahed and the diameter of the reference standards and 
samples were calculated using Image-J software (Pixel-aspect ratio = 1, known distance = 4mm). 
A calibration curve based on the area of the immunoprecipitation ring from the standard ring 
diameters can be found in Appendix 3.  
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5.7.4 NSEM 
 
NSEM analysis and quantification was completed by Micheline Letarte at INRS Institut Armand 
Frappier in Laval, Quebec. Samples were diluted with TEN buffer (10 mM Tris, 1 mM EDTA, 
100 mM NaCl pH 8.0) to an appropriate concentration. Diluted samples were then placed in 240 
µl microtubes with carbon and polyvinyl formal coated grids inserted at the bottom of the tubes. 
The tubes were centrifuged at 20 000 x g for 5 minutes. Recovered grids were dried and stained 
with 3% phosphotungstic acid, pH 6.0. Samples were then visualized under a transmission 
electron microscope. 
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Chapter 6: Production of Influenza VLPs Using the BacMam System 
 
Production of influenza VLPs in mammalian cells using the BacMam system have been 
previously reported by Tang et al (2010). From the literature and our own experience, it seems 
plausible that manipulation of production conditions has the potential to increase VLP production. 
In particular, the addition of butyric acid, valproic acid, and increasing cell concentration at 
transduction to achieve increased production. To examine these factors, sequential experiments 
were completed; by varying the concentrations from 1-5 mM and 0.25-2 mM of butyric acid and 
valproic acid, respectively; and increasing cell concentration at transduction from 0.5x106 
cells/ml to 2x106 cells/ml. Conditions were probed for VLP production with the aid of western 
blots of HA, visual inspection of reporter GFP expression and the HA assay. The starting point 
used the optimal conditions found in Tang et al (2010). Typical growth curves during VLP 
production can be found in Appendix 4a. 
6.1 Butyric Acid and Valproic Acid Additives 
 
To try and increase protein production, one dose of butyric acid or valproic acid was added to 
VLP production directly after addition of the BacMam virus. We assumed that both additives 
remained in the culture for the duration of the experiment, as cell growth was either completely 
arrested or slowed down compared to the control culture, which is one of the side effects of the 
addition of butyric and valproic acids. Visual inspection of GFP expression, as shown in Figure 
6-1 was analyzed to compare protein expression with and without the addition of butyric acid 
during VLP production at an MOI of 60 (three independent replicates were completed). Because 
of unique CMV promoter control of GFP and the influenza genes, expression profiles of GFP and 
the influenza proteins were expected to be similar. It should be noted however, that VLP 
production does not necessarily follow the same profile as simple protein production.  
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Figure 6.1:  GFP expression with and without the addition of 5mM butyric acid. 
The top row shows pictures for GFP expression in culture taken at 24, 51 and 70 hpt without the 
addition of butyric acid. The bottom row shows GFP expression in culture taken at 24, 51 and 70 
hpt with the addition of butyric acid. 
As shown in Figure 6.1, GFP expression is enhanced with the addition of 5 mM butyric acid at 
each time point. Figure 6.2 shows the HA activity (normalized to production values) measured 
from productions completed with and without the addition of butyric acid. 
 
Figure 6.2: HA activity (HAU/ml) of sucrose cushion purified HEK 293 VLPs produced 
with and without butyric acid.  
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More information on the appropriate time of harvest was also gained from this study as it was 
observed that the GFP signal decreased after 70 hours post transduction (hpt), possibly due to the 
degradation of the baculovirus viral DNA inside the cell, and started discussions of the 
appropriate time of harvest discussion, as Tang et al (2011) harvested their VLP production at 72 
hpt. At 72 hpt, cell viability was still over 90%, however there was a large amount of cell 
clumping observed, making counting difficult. Experiments from this point on were harvested 
around 48 hpt to avoid cell clumping and take advantage of maximum protein production based 
on GFP expression at 48 hpt. 
Valproic acid and butyric acid addition at different concentrations (one experiment of 0-2.5mM 
and 1-5mM for valproic acid and butyric acid, respectively) were assessed visually based on GFP 
fluorescence as shown in Figure 6.3. These concentrations were used based on the concentrations 
of butyric acid used in the previous study by Tang et al (2011) and from concentrations that have 
been previously tested in the past by members of our group for protein production in mammalian 
cells. Under the range of conditions tested, valproic acid did not appear to have a significant 
effect on GFP expression where 5mM butyric acid resulted in the most intense signal.  
 
Figure 6.3: GFP expression with the addition of butyric acid and valproic acid for HEK 293 VLP 
production.  
The top row shows GFP expression from cultures with butyric acid addition (NaBu) at 
concentrations from 1-5 mM. The bottom row shows GFP expression from cultures with valropic 
acid (ValP) at concentrations from 0.25-2 mM. 
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6.2    Multiplicity of Infection (MOI) 
 
Different MOIs were tested to pinpoint the one leading to the highest GFP and HA protein 
expression (three independent replicates). Figure 6.4 shows GFP expression at different MOIs. 
MOIs of 120 and 200 showed the most intense GFP signal in this study. These MOIs were 
chosen partly based on those used previously by Tang et al (2011) and also depended on the 
concentration of the BacMam that we produced. We did not want to add more than 10% BacMam 
by volume to the culture, so MOI 200 was the upper limit that allowed us to stay within these 
boundaries without further concentration of the virus stock.  
 
Figure 6.4: GFP expression at different MOIs ranging from 1-200 for HEK 293 VLP production. 
 
Western Blot analysis revealed that while MOIs of 120 and 200 had the strongest GFP signal, 
MOIs of 60 and 120 had similar HA band intensity as shown in Figure 6.5. This result matches 
Tang et al (2011), who observed that, above an MOI of 60, influenza protein production saturated, 
based on their NA western blot analysis (Tang et al., 2011). From this result, an MOI of 60 was 
chosen for subsequent studies. 
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Figure 6.5: HA western blot for MOIs of 1-200 for HEK 293 VLP production. 
Labels 1-5 represent MOIs of 1, 20, 60, 120 and 200, respectively. MOI 60 was chosen as the 
condition that produced the greatest amount of HA protein. 
6.3  Cell Concentration at Transduction 
 
VLP production was compared during production at two different concentrations, 1.0x106 
cells/ml and 2.0x106 cells/ml. Higher cell densities were not explored because of in-house data 
that showed that productivity of HEK 293 cells reached a plateau at 2.0x106 cells/ml for 
influenza virus production. Sucrose cushion concentrated supernatants were compared using 
the HA assay as shown in Figure 6.6. VLP production with a starting cell concentration of 
2.0x106 cells/ml had a higher HA activity than production with a starting concentration of 
1.0x106 cells/ml. Transduction at a cell density of 2.0x106 cells/ml was chosen for subsequent 
studies. 
 
 
Figure 6.6: HA activity (HAU/ml) of sucrose cushion purified HEK 293 VLPs at 
different cell concentrations. 
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6.4    VLP Characterization 
 
In order to verify the presence of VLPs, harvested supernatants were concentrated with a 
sucrose cushion and analyzed for presence of HA, NA and M1 proteins by western blot. Any 
free influenza or cell proteins in the supernatant should not be captured in the sucrose cushion 
pellet containing VLPs, thereby also serving as a partial purification step. HA activity was 
verified with the HA assay and the SRID assay. The physical presence of VLPs was verified 
and quantified by NSEM.  
Analysis by western blot confirmed the presence of HA and NA proteins in VLPs (Figure 6.7). 
HA0 is found just under 75kDa and overlaps with contaminant proteins labeled through non-
specific binding (shown in Appendix 5). The positive control, H1N1 A/Puerto Rico/8/1934 
(influenza WT), does not match the HA0 band in the VLP sucrose cushion (SC) lane because it 
was produced in the presence of trypsin, which cleaves HA0 into HA1 and HA2 (J. Chen et al., 
1998). Although WT virus needs to be produced in the presence of trypsin in cell culture to 
ensure infectivity (Le Ru et al., 2010), it is not required for the production of non-infectious 
VLPs. Therefore, HA in VLPs should remain in its uncleaved form, HA0. NA was present at 
approximately 55kDa in the VLP sample, but for the WT two extra bands at 37kDa and at 25 
kDa were also labeled. These bands could potentially be truncated forms of NA from trypsin 
cleavage during production (Air & Laver, 1989). M1 is only present in the sucrose cushion in 
very low amounts, and was confirmed to be present in the pellet by western blot shown in 
Figure 6.15.  
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Figure 6.7: HA, NA, M1 western blot of HEK SCC-VLPs and influenza H1N1/A/PR/8/1934. 
WT is supernatant from H1N1/A/PR/8/1934 and SC is SCC-VLPs, both produced in-house 
from HEK 293 cells.  
The HA assay was completed to show the agglutination activity of sucrose cushion purified VLPs. 
Figure 6.8 shows a typical profile that was obtained when completing this assay. One observation 
from this assay was that there exists a grey area, where partial agglutination occurred as 
described previously (Killian, 2008). The red circle on the left without a red drop represents the 
lower limit of agglutination, where complete agglutination of the red blood cells occurred. The 
wells enclosed by the black lines have small red dots that do not tear when the plate is inclined 
and this is where partial agglutination occurred. Finally, the last well with a non-tearing drop is 
the upper limit of agglutination. In this study, we adopted a similar methodology to Tang et al 
(2011), where they took the upper limit of agglutination as the HA titer. HA titers of 630 
HAU/ml for a 50x concentrated VLP sample that corresponds to a production value of 12.6 
HAU/ml were obtained.  
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Figure 6.8: HA assay results completed with sucrose cushion HEK 293 VLPs and 1.25% chicken 
red bloods cells. 
The circle on the left represents the point where complete agglutination occurs, and the circle on 
the right is where incomplete agglutination occurs. The area between the circles outlined by the 
box represents incomplete agglutination. 
 
The SRID assay was used to quantify the amount of HA in µg/ml. Figure 6.9A shows a picture 
of the diffusion pattern observed. The observed ring is very small, but was able to be quantified 
as 4.6 µg HA/ml in a 50x concentrated VLP sample and a production value of 0.09 µg HA/ml. 
The ring does not follow the standard pattern that SRID rings usually follow (shown in Figure 
6.9B). This could be because sucrose cushion material, which was only partially purified, was 
used instead of fully purified material (the standards). The debris in the sample could 
precipitate in the well resulting in the dark stain around the circumference1.  
 
Figure 6.9: SRID rings observed with HEK 293 VLPs (A) and 
recombinant H1N1/A/PR/8/1934 protein (B). 
  
 
SCC-VLPs and influenza virus were analyzed by visual inspection and quantified for total 
particles/ml by NSEM. Figure 6.10 and 6.11 shows zoomed-in images of both VLPs and virus 
produced in-house in HEK 293 cells (marked with black arrows). VLPs were identified as 
                                                1	  At first, we assumed there was actually no diffusion ring, but after adjusting the contrast on the picture, 
we could see that the outer ring was very close to the inner precipitation ring that it appeared there was 
only one ring.	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particles with a fringe or spike around the outside, which was assumed to be made up of 
influenza glycoproteins HA and NA. VLPs were counted to be at a concentration of 7.9x109 
VLPs/ml in a 50x concentrated sample, or 1.58x108 VLPs/ml during production. Influenza virus 
produced in cell culture is pleomorphic and consists mainly of spherical and elongated particles 
with an average size of 100 +/- 20 nm (Le Ru et al., 2010). Based on the way VLPs were 
identified and quantified for this analysis, their morphology also falls into this classification 
however the average size ranged from 100 to 300 nm by NSEM analysis. Figure 6.11 shows a 
zoomed out image of SCC-VLPs and influenza virus. In the virus sample, it was easier to identify 
influenza particles, as it is already widely known what influenza particles look like. However, it 
is clear that in the virus sample there are particles with a fringe (marked with white arrows) that 
would have been identified as VLPs had they been in the VLP sample. 
 
 
Figure 6.10: NSEM images of VLPs (A, B) and influenza virus H1N1 A/PR/8/1934 (C) at 40 
000x magnification. 
VLPs from image A resembles typical influenza particles produced in cell culture, as shown in 
image C. However, image B shows particles with unique morphology.  
100 nm 100 nm 100 nm 
A B C 
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Figure 6.11: NSEM images of SCC-VLP and virus samples.  
Black arrows represent the particles identified as VLPs (image A) or influenza virus (image B). 
White arrows represent similar looking larger particles with a fringe that could also be identified 
as VLPs that were found in both samples. 
In order to gain insight on how to store VLPs mid-process, SCC-VLPs were either stored at -
80 °C or 4 °C and analyzed after 3 weeks. Both samples showed the same HA activity (12.6 
HA units/ml), indicating that particles can be stored at either temperature with no detectable 
effect on HA activity during purification.  
6.5  VLP Purification by Iodixanol Gradient 
 
SCC-VLP samples were purified further using ultracentrifugation with an iodixanol gradient. 
Fractions (12 or 13 x 1ml) were collected from the bottom of the tube and analyzed with 
western blot, HA assay and NSEM. Figure 6.12 is the HA western blot of fractions collected 
from the iodixanol gradient ultracentrifugation. HA0 is the middle band just under 75 kDa and 
present in the iodixanol fractions at the bottom of the tube (fractions 1, 2, 3, first lanes on the 
left in Figure 6.12) and the top of the tube (fractions 11 and 12, the last two lanes on the right in 
Figure 6.12). The density at the bottom of the tube was 1.2-1.1 g/ml where at the top was 1.0 
µg/ml. Particles (including VLPs) migrate to fractions of higher density and free protein to 
those of lower density. Western blots for NA agreed with the pattern for HA while M1 was 
only found in fraction #1 (NA and M1 western blots shown in Appendix 6a). The HA band in 
top fractions show that there was a high amount of free HA protein present in the sucrose 
cushion starting material released from VLPs during iodixanol purification. 
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Figure 6.12: HA western blot of collected iodixanol gradient purified VLP fractions.  
Fraction #1 corresponds to those of higher density taken from the bottom of the 
ultracentrifugation tube and fraction #12 to those of lower density from the top of the tube.   
 
Collected iodixanol fractions where analyzed by the HA assay. Figure 6.13 shows their 
agglutination ability in HAU/ml. HA activity agrees with HA identification from the western 
blot, with the highest HA activity detected in the bottom and top fractions of the iodixanol 
gradient.  
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Figure 6.13: HA activity (blue bars, left axis) and density (red line, right axis) in iodixanol 
fractions #1-13.  
 
Iodixanol fractions of high and low density were visually analyzed by NSEM and quantified. 
Figure 6.14 shows NSEM images at 40 000 x magnification. Fraction #1 contained the highest 
amount of VLPs quantified. In addition, this fraction contained many small white particles (that 
could possibly be identified as aggregated HA proteins, or HA rosettes (Ruigrok et al., 1988)) 
as well as a baculovirus particle (rod shaped particle), both indicated by the white arrows. 
Fraction #2 and #3 both contain less white protein aggregates and less VLPs. Fraction #3 
contained less contaminant and a more homogenous population of VLPs around 100 nm. 
Fraction #12 however, contained very large pieces of membrane and fringed particles along 
with VLPs. The heterogeneity of this sample made quantification difficult, but it was found to 
contain 1.84x109 VLP/ml. This fraction also elicited a strong response on the western blot and 
HA assay, either from the fringed particles or in the form of free HA that migrated to the 
fractions of lower density. The agglutination ability of VLPs in terms of particle concentration 
is given in Table 6.1 and varied from 8.20x106 – 1.21x108 VLP/HAU. Fraction #1 contained 
the small white particles, which could be HA rosettes, fraction #12 contained the larger pieces 
of membrane. Larger particles or pieces of membrane will naturally have a better agglutination 
ability than small rosettes, as they require less to agglutinate RBCs. Issacs & Donald (1955) 
state a similar observation, where they saw that filamentous influenza had a different 
agglutination ability than spherical-like, based on its larger size. Fractions 2 and 3 had similar 
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VLP/HAU values and also contained similar looking VLPs, and did not contain rosettes or 
large pieces of membrane with HA spikes in the NSEM images like fractions #1 and #12. 
 
Figure 6.14: NSEM images of iodixanol purified VLPs at 40000x magnification. 
Black arrows indicate VLPs. White arrows indicate HA rosettes and baculovirus particles (image 
#1), and debris (image #2). 
Table 6.1: VLP/HAU for different fraction of the iodixanol density gradient 
Fraction VLP/HAU 
1 1.21x108 
2 1.55x107 
3 3.03x107 
12 8.20x106 
 
 
 
Iodixanol #1  
1.08x1011 VLP/mL 
Iodixanol #2  
2.46x109 VLP/mL 
Iodixanol #3  
8.57x108 VLP/mL 
Iodixanol #12 HEK 293 
1.84x109 VLP/mL 
100 nm 
100 nm 
100 nm 100 nm 
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6.6 Cell Pellet Analysis 
 
To try and achieve the highest possible yield, the cell pellet was examined to see if VLPs were 
still attached to the cell. Excessive cell clumping was observed during VLP production trials, 
which could have trapped VLPs. To address this issue, the cell pellet was washed with 10 
µg/ml TPCK-trypsin to favor the break-up of cell clumps and the release of trapped VLPs. In 
addition, cells were lysed with a freeze thaw cycle to explore the possibility of internally 
budded or intracellular trapped VLPs. Analysis was completed with western blot, HA assay and 
NSEM. 
Figure 6.15 is the HA, NA and M1 western blot of SCC-VLPs, cell pellet wash and lysate. 
Western blot analysis of the cell pellet washes showed bands for HA0 and NA near the 70kDa 
and 50kDa mark, respectively, and a very faint signal for M1 at 25kDa. All proteins were 
detected in the cell lysate with more intense bands compared to the cell wash and sucrose 
cushion (sucrose cushion western blot is shown in Figure 6.7).  
 
Figure 6.15: Western Blot of SCC-VLP (SC), cell pellet wash (W) and cell pellet lysate (L).  
NIBSC anti-HA and NA and Abcam anti-M1 antibodies were used for each protein.  
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Analysis with the HA assay shown in Figure 6.16 indicated that there was active HA released 
from the cell pellet wash and found in the cell lysate. The amount of active HA released into 
the supernatant was slightly higher than that found in the pellet.  
  
Figure 6.16: HA activity of SCC-VLPs, supernatants from cell pellet wash and cell lysate 
(normalized).  
To check if there were any VLPs associated with the pellets and that the HA activity detected 
in the pellet (wash or lysate) was not only from the release of HA in the form of free protein, 
samples were analyzed with NSEM for VLPs and quantified. Figure 6.17 shows NSEM images 
of released particles from the cell wash at 40000x magnification (A) and zoomed in (B). The 
cell pellet wash showed a wide range of particles with a fringe, including a cluster of round 
particles just under 100 nm that closely resembled influenza virus particles (black arrow), as 
well as very large particles up to 400 nm (white arrows). They were quantified as 3.07x108 
VLPs/ml, which is actually higher than the sucrose cushion. HA activity was lower for the cell 
wash compared to the sucrose cushion, indicating that particles with a fringe in the cell wash 
sample may have been misidentified as VLPs. Nevertheless, this confirmed that the HA activity 
found was not only from free protein, but from trapped VLPs that were released from the non-
lysed cell pellet.  
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Figure 6.17: NSEM images of VLP particles from the cell pellet wash. 
Image A is was done at 40000x magnification and image B shows a zoomed in view of a cluster 
of VLPs identified by the black arrows in image A. White arrows indicate large particles with a 
fringe that were not identified as VLPs due to their large size.  
 
As for the cell lysate, particles with a fringe were also present, as shown in Figure 6.18. They 
were counted to be present at a concentration of 1.43x108 VLPs/ml, about the same level as 
what was observed in the sucrose cushion purified VLPs. Like other samples, both round and 
pleomorphic particles were found.  
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Figure 6.18: NSEM image of released particles from the cell lysate.  
Those counted as VLPs are marked with back arrows and white arrows indicate particles not 
counted due to their large size.  
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Chapter 7: Production of Influenza VLP using the BEVS 
 
In order to compare with the VLP production in HEK293 cells, a series of experiments varying 
MOI and time of harvest were completed to probe for the best condition. VLP production was 
completed with MOIs chosen ranged from 0.3-2.1 (Table 7.1), and the best found was HA = 1, 
NA = 0.1, M1 = 1, or a total of 2.1, based on western blot analysis (Appendix 7). Cell density at 
infection was 2.0x106 cells/ml and a higher MOI was chosen in order to harvest before viability 
dropped below 70%. Conditions were analyzed for the presence of influenza proteins in the 
supernatant by western blot. Typical growth curves and cell diameter profile during VLP 
production can be found in Appendix 4b. 
Table 7.1: Different combinations of MOI probed for the best VLP production in Sf9 cells 
Protein HA NA M1 Total MOI 
MOI 1 1 1 3 
0.5 0.5 0.5 1.5 
0.1 0.1 0.1 0.3 
1 0.1 0.1 1.2 
0.1 1 0.1 1.2 
0.1 0.1 1 1.2 
1 0.1 1 2.1 
7.1  VLP Characterization 
 
To verify the presence of VLPs, harvested supernatants were concentrated with a sucrose 
cushion and analyzed for the presence of HA, NA and M1 proteins by western blot. HA activity 
was verified with the HA assay and the SRID assay. SCC-VLPs were also analyzed with 
NSEM. 
Analysis of SCC-VLPs by western blot confirmed the presence of HA, NA and M1 proteins in 
the VLPs (Figure 7.1). HA0 is between the 75 and 50 kDa marker, NA is present at 50 kDa 
markers and also in truncated forms at 37 and 25 kDa. M1 is present at 25 kDa and GP64 
between 75 kDa and 50 kDa.  
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Figure 7.1: GP64, HA, NA, and M1 western blot of Sf9 SCC-VLP.  
NIBSC anti-HA and NA, Abcam anti-M1 and eBioscience anti-GP64 antibodies were used.  
  
SCC-VLPs and virus were analyzed by visual inspection and quantified for total particles/ml by 
NSEM. Figure 7.2 shows images of both VLPs and influenza virus produced in-house from the 
Sf9 and HEK 293 systems, respectively. VLPs were identified as particles with a fringe around 
the outside, which is assumed to be made up of influenza glycoproteins HA and NA. A 
concentration of 2.34x1011 VLPs/ml in a 40x sample, corresponding to a production value of 
5.85x109 VLPs/ml was observed. Baculovirus particles are clearly present in both images in a 
higher amount than VLPs. Total baculovirus particles were quantified to be present at a 
production concentration of 1.21x1011 BV/ml, which corresponds to 20x more total BV 
particles than VLPs. The morphology of VLPs produced from Sf9 cells was uniform, 
consisting of spherical particles around 100 nm in size.  
 
25#
37#
100#
75#
50#
150#
250#
20#
NA#
#
M1#
#
HA0#
#
GP64#
 
 
 
49 
 
Figure 7.2: NSEM images of Sf9 SCC-VLP (A) and H1N1/A/PR/8/1934 (B) samples.  
Black arrows indicate VLPs and virus particles.   
 
The HA titer for Sf9 produced VLPs was 336 HAU/ml. Based on ratio of BV/VLP made from 
NSEM quantification, an estimation of the HA activity from VLP particles was roughly 
calculated to be 15.6 HAU/ml or 3.78x108 VLP/HAU. However, these values were calculated 
(Appendix 2) based on the assumption that both particles have the same agglutination ability. It 
may not be completely accurate to say that because the physical concentration ratio of BV:VLP 
is 20:1, that the HA activity from BV particles is 20 times stronger than the HA activity from 
VLPs. Agglutination ability largely depends on the size of the particle. An HAU is defined as 
the number of particles needed to agglutinate red blood cells, and it is currently unknown if it is 
the same for influenza VLPs and BV tagged with HA.  Thus, this caveat illustrates the 
complications with influenza VLP quantification, especially in the case when HA-tagged 
contaminants are present.  
To gain insight on how to store VLPs mid-process, SCC-VLP VLPs were either stored at -
80 °C or 4 °C for 3 weeks before analysis by the HA assay. Samples stored at -80 °C had an 
HA activity of 400 HA units/ml while 4 °C samples had 530 HA units/ml. There is not a huge 
difference in HA activity, although storage of sucrose cushion samples at 4 °C appears to be the 
best option during purification steps. The activity before storage was not tested, however the 
lower HA activity from storage at -80 °C could be due to the thawing step. Both VLPs and BV 
could have HA activity associated with them and despite the fact that 1% sucrose was used as a 
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cryoprotectant in the re-suspension buffer, there still could be loss of functionality due to the 
freeze/thaw cycle.  
From the SRID assay, 15.15 µg HA/ml was detected in a 40x concentrated VLP sample, which 
corresponds to a production value of 0.38 µg HA/ml. The ring formed in this case followed the 
same pattern as that of the purified standard (Figure 6.9b). This is could be from the low about 
of cell debris found in the NSEM images of the SSC-VLPs. 
7.2  Purification by Iodixanol Gradient 
 
SCC-VLP samples were purified using ultracentrifugation with an iodixanol gradient. Fractions 
of 1 ml were collected from the bottom of the tube and analyzed with western blot, HA assay 
and NSEM. 
Figure 7.3 shows the HA western blot of fractions collected. HA0 was present in all fractions, 
showing poor separation with this method, however higher band intensity was still seen in the 
bottom and top fractions. These bands represent free HA, HA associated with VLPs and HA 
associated with BV. The density at the bottom of the tube was 1.2-1.1 g/ml where at the top it 
was 1.09 µg/ml. Figure 7.4 shows the profile of the baculovirus envelope protein, GP64. 
Following a similar pattern to HA, GP64 is in every fraction, concentrating in the bottom and 
top fractions. Particles (including VLPs and BV) should migrate to fractions of higher density 
and free protein to those of lower. Western blots for NA and M1 agreed with the pattern seen 
here for HA (NA and M1 western blots can be found in Appendix 6b). It is not surprising that 
baculovirus is co-purified with influenza VLPs, as it is a common problem previously reported 
by other studies (Margine et al., 2012; Pushko et al., 2005).  
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Figure 7.3: HA western blot of collected iodixanol gradient purified Sf9 VLP fractions 
 (#1, bottom to #13, top) with NIBSC anti-HA sheep serum.   
 
Figure 7.4: HA western blot of collected iodixanol gradient purified Sf9 VLP fractions 
(#1, bottom to #13, top) with eBioscience anti-GP64 sheep serum.   
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Collected iodixanol fractions were analyzed by HA assay (Figure 7.5). All fractions had HA 
activity, which agrees with the western blot of iodixanol fractions. This is likely due to 
inefficient separation of VLPs, host cell components or BV associated with HA. However, the 
pattern shows the highest HA activity in fractions 1-4 and 11 and 12. This result also matches 
the GP64 western blot, which has the strongest bands in fractions 1-4 and 11-13.  
 
 
Figure 7.5: HA activity (blue bars, left axis) and density (red line, right axis) in iodixanol 
fractions #1-13. 
Iodixanol fractions (2, 3, 9, 12) were analyzed by NSEM (Figure 7.6, 40 000x magnification). 
VLPs had similar concentrations in each of these fractions, from 1.89-2.86x1010. Baculovirus 
particles on the other hand, were mainly migrating to fraction #9, as indicated by the BV to 
VLP ratio shown in Figure 7.7. Fraction #9, which contained the lowest HA activity of those 
fractions sent for NSEM quantification, had the highest BV count at 1.3x1012 VLP/ml, 69 times 
higher than VLPs. Fraction #2 had the lowest count with 2.61x1011 BV/ml, still 9 x higher than 
VLPs. The sucrose cushion starting material had a BV to VLP ratio of 20, showing that the 
iodixanol gradient separated BV from VLPs, but as previously shown on the western blot, not 
completely. 
The agglutination ability of the VLPs in each fraction is illustrated in Table 7.2 and shows that 
the VLP agglutination ability is not very consistent ranging from 5.76x107 to 7.40x108 
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VLP/HAU. This could be due to the distribution of BV throughout the gradient, which may not 
have a consistent amount of HA taken into its membrane, but still contributes to this value, 
skewing the VLP/HAU calculated value. 
 
Figure 7.6: NSEM images of iodixanol purified Sf9 VLPs.   
Black arrows indicate VLPs, white arrows indicate baculovirus particles and the white circle in 
Iodixanol #2 shows the glycoprotein spikes on the baculovirus particle.   
 
Figure 7.7: BV to VLP ratio in NSEM quantified Sf9 VLP iodixanol fractions. 
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Table 7.2: VLP/HAU values for fractions of the iodixanol density gradient 
Fraction VLP/HAU 
2 5.76x107 
3 1.08x108 
9 7.40x108 
12 1.31x108 
 
7.3  Cell Pellet Analysis 
 
From western blot analysis, there was a significant amount of HA, NA and M1 proteins found 
to be in the cell lysate. TPCK-trypsin cell pellet wash and cell lysate analysis was performed to 
determine if there were internally budded VLPs or some stuck to the cells during production. 
Western blot and HA assay were used to analyze samples.  
Western blot analysis revealed release of each influenza VLP proteins and GP64 in the wash 
and lysate as identified in Figure 7.8.  
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Figure 7.8: HA, NA, M1 and GP64 western blot of cell pellet wash and cell pellet lysate.  
NIBSC anti-HA and anti-NA, Abcam anti-M1 and eBioscience anti-GP64 antibodies were used.  
 
Analysis of the wash and cell lysate for Sf9 produced VLPs shows that the HA activity from 
sucrose cushion concentrated VLPs is much stronger than both the cell wash and lysate (all 
normalized based on concentration factor), as depicted in Figure 7.9. This indicates that HA 
protein was released from the wash and was also present in the cell pellet, in agreement with 
western blot results. However, it also shows that the HA is not as functional in terms of 
agglutination ability as those released into the supernatant with VLPs or BV. 
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Figure 7.9: HA activity (HAU/ml) of sucrose cushion purified Sf9 VLPs, supernatant 
from cell pellet wash and cell lysate. 
  
0	  
50	  
100	  
150	  
200	  
250	  
300	  
350	  
400	  
450	  
Supernatant	   Cell	  Pellet	  Wash	   Cell	  Lysate	  
	  H
A	  
un
it
s/
m
L	  
 
 
 
57 
Chapter 8: Discussion 
 
8.1  Identification/Quantification Limitations 
 
The methods used to identify the best conditions from a designed experimental space were 
qualitative (western blot, GFP visual inspection), and were only based on the presence of 
influenza antigens associated with the VLP (western blot and HA assay), giving no information 
on their physical characteristics or the number of total particles. These results highlight the 
difficulties that researchers currently face regarding quantification of influenza VLP process 
development. To further optimize both systems, clearer objectives and limitations need to be 
outlined during experimentation such as the minimum MOI that will give the highest production 
of VLPs in the smallest time period. However, in order to complete such an optimization, 
appropriate quantification techniques are in need.  
An ideal quantification or identification method to be used in process development needs to be 
compatible with crude samples. To be compatible the method must be able to discriminate the 
end production from other material (debris, cellular proteins, vesicles, baculovirus particles) that 
could cause some kind of interference, have a low enough detection/quantification limit and be 
relatively quick in order to process a large number of samples in a reasonable amount of time. 
One of the main problems of current protocols is the low limit of detection. For example, during 
production with the Bacmam system, crude samples were tested with the HA assay which 
resulted in zero HA activity in part due to a limit of detection of 40 HA units/ml (Hirst, 1942; 
Szretter, Balish, & Katz, 2006). A 50x SCC-VLP sample had a reading of 630 HA units/ml, 
which corresponds to 12.6 HA units/ml when normalized to the volume of the supernatant. This 
problem can be overcome with sample concentration, but creates other problems which still limit 
process development such as laborious sample preparation, potential loss due to unknown 
product stability, and the general treatment of the step from concentration to assay readout as a 
black box because it is not possible to identify where product loss or low HA values are coming 
from; the production conditions or the downstream processing steps. Another constraint for this 
method is related to the purity of samples; HA activity from contaminant particles in samples 
containing HA (i.e vesicles, baculovirus) can enhance the HA activity, as this method cannot 
differentiate between HA activity from VLPs or other sources. When HA activity values were 
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reported in previous influenza VLP studies they have not considered the contribution from HA-
labeled baculovirus. The problem of baculovirus contamination is widely acknowledged in 
purification strategies and immunization challenges and has lead to regulatory consideration 
(Haynes, 2009; Krammer, Schinko, et al., 2010; Margine et al., 2012; Palomares & Ramírez, 
2009; Vicente et al., 2011). Given that there is still contamination at the end of purification, it is 
clear that having in-line quantification tools that can discriminate between influenza VLPs and 
baculovirus are needed.  
Although the SRID assay is heavily relied upon, HEK 293 SCC-VLPs were difficult to analyze 
by the SRID assay due to their small ring diameter (Figure 6.9a). Additionally, the ring was 
abnormally dark, which could indicate the presence of precipitation. HA is prone to aggregation, 
especially in concentrated mixtures, which VLPs usually are. Large aggregates may prevent 
proper diffusion, precipitation and interfere with readings (Apostolov & Fishman, 1967). 
Additionally, this method requires a long processing time (1-1.5 days), and has low sensitivity 
(Nilsson et al., 2010; Wood et al., 1999; Wood, Schild, Newman, & Seagroatt, 1977). The WHO 
is encouraging development of alternative methods that can replace SRID-based quantification 
(WHO, 2006). This initiative is targeted towards quantification of influenza virus-derived 
vaccines, but VLP process development could greatly benefit from these advances as well. 
With regards to the western blot, another commonly used method for VLP characterization; 
interference from contaminating material is a problem, especially when non-purified samples are 
tested. For HA and NA, polyclonal anti-HA or NA sheep serum were used, which resulted in 
labeling many non-specific bands. This makes analysis confusing and time consuming. 
Monoclonal antibodies alleviate some of these problems, however there is still non-specific 
labeling from secondary antibodies. Therefore, western blot is not a suitable method for in-
process sample analysis.  
Electron microscopy is the only method currently available that gives information on total 
particles, in terms of morphology, size and concentration. The drawbacks of this technique are 
the price of equipment and level of expertise needed to analyze and run samples. Additionally, as 
microscopy counts are based on visual enumeration, samples need to be pure enough, making this 
method difficult for the analysis of crude samples collected upstream of purification. Currently, 
there is no other option to validate the physical presence of VLPs. Past studies that have used this 
 
 
 
59 
method do not give the production or final concentration of total VLPs/ml, and focused more on 
morphological aspects of the particles (Krammer, Schinko, et al., 2010). Additionally, most 
pictures given thus far of VLPs have been very close up images of just the VLPs, not giving any 
indication what the rest of the sample may contain. Total concentration of VLPs is an important 
number to report, as the concentration of total particles in the vaccine formulation is one of its 
defining characteristics, apart from the amount HA present. Additionally in terms of process 
development, the concentration of total VLPs produced can be a good marker for process 
efficiency.  A quantification method that can report total VLP concentration accurately and 
rapidly would greatly aid the process development process. Thompson et al (Thompson et al., 
2013) indicate several potential methods for total and antigenic methods that could fill this need.  
8.2 HEK 293 vs. Sf9 IVLP Production 
 
Production values for influenza VLP from the Sf9 and HEK 293 systems are presented in Table 
8.1 
Table 8.1: IVLP Production HEK 293 vs. Sf9 
 SRID 
(ug 
HA/ml) 
HA Assay 
(HAU/ml) 
VLP/HAU 
(Iodixanol 
Fractions 
2,3) 
VLP/ml VLP/cell Contamin
ation 
HEK 0.09 +/- 
0.01 
12.6 +/- 
2.50 
 
5.76x107 
 
1.58x108 79 Vesicles, 
trace BV 
particles 
Sf9 0.38 +/- 
0.04 
 
 
336 +/- 
67.2 
 
 
1.55x107 
 
5.85x109 2925 1.21x1011 
BV/ml 
Sf9 produced VLPs at a concentration of 5.85x109 VLP/ml while HEK 293 produced VLPs at a 
concentration of 1.58x108 VLP/ml.  Therefore, it appears the Sf9 system is better in terms of 
productivity of VLPs/cell (both produced at 2.0x106 cells/ml over a course of 48 hours). In 
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terms of HA activity, the Sf9 SCC-VLP sample had 336 HAU/ml and HEK 293 had 12.6 
HAU/ml. However, the large amount of BV present in Sf9 SCC-VLPs must be taken into 
consideration when looking at this value, as the true amount of HA activity from VLPs or BV 
is not completely clear. By pairing NSEM quantification values and those from the HA assay, 
the agglutination ability (i.e the number of particles that it takes to agglutinate red blood cells, 
VLP/HAU) were calculated to estimate the quality of the VLPs produced. The HEK 293 SSC-
VLP sample had a better agglutination ability than the Sf9 SCC-VLP sample (9.60x106 vs. 
4.48x108 VLP/HAU). This can be attributed to the contribution from the large particles with 
HA spikes (100 < VLP < 400 nm in diameter) found in the HEK 293 VLP samples, as larger 
particles have a better agglutination ability. However, in iodixanol fraction 2 and 3 for both 
systems, similar agglutination ability was observed, 1.55x107 VLP/HAU for HEK 293 and 
5.76x107 VLP/HAU for Sf9. In these fractions, there was the least amount of contaminant in 
the form of BV or large particles with HA spikes, showing that their actual agglutination ability 
may be closer when contaminants are not skewing the values. However, these calculations are 
just an estimation, as they are based on the overarching assumption that BV and VLPs have the 
same agglutination ability (calculated with NSEM ratios to distinguish the difference between 
BV and VLP HA activity, Appendix 2) and do not take into account the fact that some HA 
activity could also be from free, aggregated, rosette-form HA or large vesicles with HA spikes 
not accounted for with VLP quantification by NSEM. Despite its limitations, the HA assay is 
the only method currently available to characterize VLPs from different production systems 
from a quality point of view (i.e amount of active HA antigen). Even though higher level 
calculations are based on shaky assumptions, overall the HA assay is still able to give a readout 
to compare the two systems, which tells us that the Sf9 system produces more active HA than 
the HEK 293 platform, but from the HA ability calculated in iodixanol fraction 2, that the VLPs 
produced are of similar quality. 
From analysis of the Sf9 cell pellet (Figures 7.11), it is clear that the HA that remains in the pellet, 
while large in quantity by western blot analysis, is not very functional. However, in the HEK 293 
system (Figure 6.16), the HA in the pellet had similar activity to its counterpart in the supernatant, 
indicating that VLPs were still attached to the pellet or inside the cell in the correct formation in 
vesicles. This brings up the question of where these VLPs were coming from, either attached to 
the cell after budding/incomplete budding or from inside the cell. Influenza particles bud from 
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the cell membrane (Rossman & Lamb, 2011), and there are no reports of internally budded 
influenza particles. However, there are cases of HIV particles budding from internal multi-
vesicular bodies (Welsch et al., 2007), where they should normally bud from the plasma 
membrane, like the influenza virus. Considering that more than one influenza protein has the 
potential to induce budding (Rossman & Lamb, 2011) this explanation may hold some merit in a 
VLP system. In addition, the presence of particles that are physically similar to what we 
identified as VLPs in the virus sample, could mean that system vesicles from the HEK 293 
system have taken HA or NA into their membrane. These vesicles may have budded from the cell 
membrane, but also may have budded from internal membranes, then released upon cell death.  
Overall, Sf9 VLPs are produced at a higher level than HEK 293 when comparing production at 
the same cell density (Table 8.1). The Sf9 system has the challenge of baculovirus contamination, 
and the HEK 293 may also have a similar problem but in terms of cell vesicles (Section 8.4). The 
next step in these studies would be to compare the immune response generated by each particle. 
Margine et al (Margine et al., 2012) completed a study of this type but did not purify out the BV. 
In order to truly compare the two systems, a purified sample of VLPs from both systems need to 
be compared. 
8.3  Structural Matrix Protein 
 
One of the main differences between Sf9 VLPs and HEK 293 VLPs was the presence of the 
matrix protein (M1) in Sf9 VLPs. M1 was not present on the western blot of HEK 293 SCC-
VLPs, but was in the pellet. For Sf9 VLPs, it was present in both the sucrose cushion purified 
samples and the cell pellet. Previous reports indicate that M1 is able to form VLPs on its own 
(Gómez-Puertas, Albo, Pérez-Pastrana, Vivo, & Portela, 2000; Latham & Galarza, 2001) 
however this was later implied to be a result of the production system used (B. J. Chen et al., 
2007). M1 does not possess the signal for transport to the cell membrane, but is assumed to be 
recruited by binding to the cytoplasmic tails of HA, NA and/or M2. However, M2 has the only 
verified sequence to which M1 binds (B. J. Chen, Leser, Jackson, & Lamb, 2008). Chen et al 
(B. J. Chen et al., 2007) showed in a mammalian plasmid-transfection system that HA in 
combination with M1 resulted in VLPs, but the addition of M2 enhanced VLP production. 
Additionally, Tang et al’s study of Bacmam VLP production in HEK 293 adherent cells also 
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found M1 in the supernatant without expression of M2. It is still not clear why M1 remained in 
the pellet for the case of VLP production in HEK 293 suspension cells. The addition of M2 
could potentially increase yields, but the presence of HA and NA, based on previous studies, 
should be enough to recruit M1 to the cell membrane for VLP formation. This has lead to 
hypothesize that some intracellular function is blocking the recruitment of M1 to the cell 
membrane for incorporation during budding in this cell system.  
Regardless of the reason why M1 is or is not incorporated into the VLP, its presence or lack 
thereof could have a lasting effect on the VLPs produced. It may not be of significance in terms 
of its antigenic potential, but particles could be structurally compromised as M1 is the 
structural backbone of the influenza virus (Rossman & Lamb, 2011). This is an important point 
for bioprocessing, where producing stable particles that can withstand downstream processing 
is sought.  
This may also be an explanation for the large amount of debris present in sucrose cushion and 
iodixanol purified HEK 293 VLPs (Figure 8.1). 
Figure 8.1: 10 000x magnification images of HEK 293 SCC-VLP (A) and Sf9 SCC-VLP (B). 
Black arrows represent VLPs and white arrows cell debris.  
This study has not verified that some of the debris in the NSEM images was free HA protein 
(i.e protein that was associated with VLPs but was released due to particle destruction), 
however there is a reason to believe it could be as there was a large HA band in the lower 
density fractions of the iodixanol gradient purification. Free protein will migrate to lower 
density compared to VLPs, which are heavier. The potential presence of free protein in both the 
sucrose cushion and iodixanol purified samples could indicate two important points about HEK 
293 VLP stability. The particles that were pelleted during the sucrose cushion could have 
500 nm 500 nm A B 
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collapsed, resulting in the presence of free HA. Next, during the iodixanol gradient purification, 
the existing free HA could have migrated to the lower density fractions plus any new free HA 
from destroyed particles that could not withstand the second ultracentrifugation. Sf9 VLPs did 
not have as much debris in their pictures and were produced at a level of 1.5 logs higher than 
their counterparts produced in HEK 293. The hypothesis that the presence of M1 increases 
particle stability and thus yields is partially supported from our observations of both systems. 
Chen et al (B. J. Chen et al., 2007) have shown that when M1 is expressed with HA, rather than 
HA alone, VLP production was increased. Additionally, the presence of M1 could be the 
reason for a more uniform and traditional cell culture influenza-like particle morphology in the 
Sf9 system, as it has been shown that the structure of M1 further determines whether the virus 
particle is spherical or filamentous (Calder, Wasilewski, Berriman, & Rosenthal, 2010).  
Another hypothesis connected to the strong presence of M1 in the Sf9 system and higher 
production levels could be due to the construct used for VLP production. One baculovirus 
containing all three genes in addition to GFP was on present on the Bacmam construct, while in 
the insect cell system three separate baculoviruses were used to produce each influenza protein. 
This could be a large amount of stress on the baculovirus, and limit protein production, 
resulting in lower levels of VLP production, or insufficient amounts of M1 produced. 
Considering that the Sf9 system used three separate baculovirues for VLP production, a more 
accurate comparison may be with three separate bacmam constructs. However, given that the 
difference in production was significantly higher, at 1.5 logs, it is possible that the Sf9 system 
will still prove to be superior despite upstream improvements made by changing the bacmam 
constructs. 
8.4 Contamination 
 
The motivation behind producing VLPs in HEK 293 cells was to avoid contamination with 
baculovirus (Tang et al., 2011). However, we encountered potential contamination from another 
source with this production system. Western blots of uninfected HEK 293 cell culture showed a 
contaminating band at 75 kDa (Appendix 5). It is hypothesized that this band could be from 
cellular proteins associated with secreted vesicles, which are budded particles that perform a 
variety of functions in a cell’s secretory system (Denzer, Kleijmeer, Heijnen, Stoorvogel, & 
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Geuze, 2000). Past studies on the development of purification of retroviruses produced in cell 
culture have shown the presence of contaminating cell membrane vesicles (Abe, Miyanohara, & 
Friedmann, 1998; Bess, Gorelick, Bosche, Henderson, & Arthur, 1997; Gluschankof, Mondor, 
Gelderblom, & Sattentau, 1997; Segura, Garnier, & Kamen, 2006). Gluschankof et al state they 
are between 50-500 nm in size and make up 50-75% of total particles produced according to 
NSEM analysis. Considering the particles present in the NSEM influenza image that could be 
labeled as VLPs (Figure 6.11 b), there exists the possibility that these particles are vesicles that 
have taken up HA or NA during budding. This observation brings up an important point of how 
to define VLPs. On a western blot, HA assay or SRID assay, a vesicle or VLP would be 
indistinguishable, if they have both incorporated HA and/or NA during the budding process and 
are co-purified together. NSEM analysis however, allows for visual inspection of the particles. If 
VLPs are identified as particles with a fringe, then mainly all the vesicles could be identified as 
VLPs. Additionally, under this definition it could be argued that vesicles could be used as a tool 
to aid VLP production, and increase overall yield. However, secretory vesicles could contain cell 
waste, including proteins and nucleic acids that need to be quantified and removed or inactivated 
in final vaccine formulations. Therefore, there is the possibility that accompanying vesicles could 
end up to be more of a burden, than an aid during VLP process development.  If VLPs are 
defined as particles that fall into the same shape and size of influenza virus, then vesicles will not 
fall into this definition, and current production of VLPs is overestimated. The presence of these 
particles could also complicate purification, resulting in a similar contamination problem that 
exists with VLP production in the baculovirus-insect cell system. Finally, the question of whether 
these particles have the ability to induce an immune response is another important consideration 
that will need to be eventually addressed.  
For Sf9 VLPs, it is clear here that the major contaminant is baculovirus, as vesicles were not 
detected in the NSEM images. Previous reports by Krammer et al (Krammer, Schinko, et al., 
2010) report the presence of BV contamination in supernatant VLP samples at a level of 108 and 
106 PFU/ml from Sf9 and High Five cells, respectively. Our report of 1011 total particles/ml is 
higher than previously mentioned. This could be due to variation between titering methods, 
which have shown when completed at different times by different operators has lead to 1-2 logs 
variation in titer (Shen, Meghrous, & Kamen, 2002).  Furthermore, quantification is done in PFU, 
which is always less than total particles. Margine et al (Margine et al., 2012) report an enhanced 
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immune response from BEVS derived VLPs compared to mammalian produced VLPs, but 
attribute this enhanced immunogenicity to contaminant baculovirus that triggers the innate 
immune response. As a consequence of this finding, past immunological studies done with VLP 
preparations from the BEVS system do not communicate the true immune response associated 
with influenza VLPs, but rather that from VLPs and BV. Additionally, in the study of HEK 293 
VLPs produced by Bacmam transduction, Tang et al (Tang et al., 2011) have contradictory 
results to Margine et al for the immunogenicity of mammalian produced VLPs, which were much 
stronger compared to what was found from the transfection based system that Margine et al used. 
Tang et al do mention that there was not any infectious residual BV in VLP formulations, but BV 
DNA was detected by PCR, which could still mean the presence of defective BV particles that 
could trigger an immune response. In our purified samples from Bacmam productions, residual 
BV was detected in NSEM images. Therefore, immunological studies with VLPs from any BV 
system (infection or transduction) should be completed with purified VLPs free of any viral 
contaminant that may skew results.  
Considering the concern from regulatory agencies with human vaccines containing any live virus 
or genomes, BV must either be inactivated or removed for these VLPs to be considered human 
vaccine candidates. Chemical and UV inactivation has been shown to eliminate both interferon 
and immune-enhancing activity of BV (Hervas-Stubbs, Rueda, Lopez, & Leclerc, 2007) and GE 
healthcare has shown that baculovirus can be separated from influenza VLPs using Capto Q ion-
exchange chromatography in flow through mode (GE_Healthcare, 2012), where BV and DNA, 
which are assumed to be more negatively charged, bind to the column but the VLPs are allowed 
to flow through and are collected before subsequent elution of contaminant material. They do not 
indicate if the starting material was pre-purified or concentrated and how much BV was initially 
present, however, efficiency of BV separation does depend on the condition of the VLP feed and 
contaminant concentrations. VLP recovery varies from 60-80% for H5N1 VLPs and 39-43% for 
H1N1 VLPs.  One of the benefits of purifying VLPs in flow-through mode is reducing potential 
shear forces and stress from binding and elution that could affect the stability of the VLPs. 
Another potential method would to use affinity chromatography in flow through mode, here BV 
or vesicles would bind to the column but VLPs are allowed to pass through. For this to work 
efficiently the column would have to target BV proteins or vesicles proteins (i.e GP64, VP39, 
heat shock proteins). However a potential problem would arise if VLPs have taken a considerable 
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amount of BV or vesicle proteins in their membrane during budding, allowing for the VLPs to 
bind to the column as well. Another study (Gerster et al., 2013) showed that baculovirus can be 
purified from cell culture supernatant on a HPLC monolithic system by salt elution at 450 mM. 
An in-house HPLC method developed by our lab (data not shown) has found that infectious 
influenza particles elute from the same column at 650 mM salt. This could provide a potential 
method for separation. Other existing chromatography protocols for influenza virus purification 
include affinity, size exclusion and anion-exchange in flow through mode (GE_Healthcare, 2012; 
Kalbfuss, Wolff, Morenweiser, & Reichl, 2007; Opitz, Salaklang, Büttner, Reichl, & Wolff, 
2007). Additionally, Medicago Inc purifies plant-produced influenza VLPs with affinity 
chromatography (D’Aoust et al., 2008). All of this data should be a good starting point to begin 
to develop a separation technique for VLP and BV, or even just purification of VLPs from other 
platforms without such significant contamination as scalable methods need to be developed. The 
monolithic and flow-through modes seem to be the most promising in terms of binding capacity 
and maintaining particle stability.  
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Chapter 9: Conclusions and Recommendations 
 
Based on the results from this work, there are multiple conclusions and directions in which to 
move forward. It is evident from comparing the two production systems that the BEVS VLP 
production system is superior in terms of VLP production ability and quality of particles 
produced. It produced VLPs at a concentration of 5.85x109 VLP/ml while the concentration 
achieved with the Bacmam HEK 293 system was 1.21x108 VLP/ml. Additionally, VLPs 
produced in insect cells were more homogeneous and resembled influenza particles produced in 
cell culture, while the VLPs produced in mammalian cells were more heterogeneous in shape and 
size. From this conclusion, two other can be drawn; firstly that the incorporation of M1 in the 
VLP has an influence on the type of VLP produced. The VLPs found in the supernatant produced 
in the HEK 293 system had very little or no M1 as detected by western blot, even though it was 
included in the expression cassette. This unexpected finding leads to the conclusion that the lack 
of M1 may have played a role in terms of the quality of VLPs produced from this system. M1 is 
the structural backbone of the influenza virus, linking the envelope glycoproteins to the RNA 
inside the particle. Additionally, it has been hypothesized that M1 determines the shape of the 
influenza particle (Calder et al., 2010). Without this important protein, VLPs of varying size and 
lacking structural stability could have been produced. Secondly, the wide variation of shape and 
size for mammalian produced VLPs could have been influenced by the production of cellular 
vesicles that take up HA and/or NA in their envelope when exiting the cells. The production of 
cellular vesicles with influenza proteins was not a problem in the Sf9 system as shown by NSEM 
images. However, there was a problem of BV contamination in the Sf9 system, where BV was 
produced at a level of 1.21x1011 BV/ml. This is the first time to our knowledge that these 
production values (VLPs/mL and BV/ml) have been given.  
With regards to quantification, throughout this project it was made very clear to us how difficult 
VLP process development is without a proper quantification method to complement these studies. 
Current quantification protocols are more suitable for purified material, which makes the analysis 
of in-process samples challenging due to the presence of contaminants and insufficient levels of 
identification/quantification. 
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To move forward in VLP process development, multiple steps need to be completed. Firstly, a 
quantification technique that is appropriate for in-process samples is needed. However, in order 
to fully develop such a method, a purified “gold standard” VLP will be needed for validation. As 
a result, more work needs to be done on separating VLPs from BV. There have been some 
preliminary studies and protocols (GE_Healthcare, 2012; Gerster et al., 2013), but this is only the 
beginning of many more studies that need to be completed. Another route is to use a system 
where the BV is able to infect the cell and deliver genes of interest, but unable to complete the 
budding process (Marek, van Oers, Devaraj, Vlak, & Merten, 2011). In the case of mammalian 
produced VLPs, where BV contamination is not a problem, ultracentrifugation purification 
should be sufficient for a purified sample, but the large amount of debris and system vesicles 
needs to be separated.   
Once a quantification protocol has been developed, process optimization in bioreactors assessing 
aspects such as DO, agitation rate, time of harvest, MOI, and temperature can be further 
optimized. Finally, this will also allow further comparisons for production systems such as 
mammalian transfection vs. insect, plant vs. insect or mammalian vs. plant.  Finally, VLP 
stability and storage conditions need to be assessed. 
. 
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Appendix 1A: Flow Cytometry Total Baculovirus Particle Calculation 
The concentration of total baclovirus particles was calculated based on the following (1):  Viral  Particle  Concentrationml =   C!×D×1000×50000C!×Vol                     (1) 
 
Where: 
CV and CF: average particle counts for viral particles and flowset, respectively. 
D:  dilution rate of the viral solution  
Vol: volume (ul) of the diluted solution taken for the sample preparation 
1000: final volume of the sample. 
50000: particle concentration of the diluted flowset 
Three counts were taken for each virus that was quantified. An example of particle counts is 
given below for the P2 viral stock of HA under polyhedron control. 
Appendix 1A Table 1.1: FC BV and flow set counts 
Count # 
Particle 
Count (CV) 
Flow Set 
Standard 
Count (FS) 
1 1194 794 
2 1223 973 
3 1086 944 
Average 1167.666667 903.6666667 
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Appendix 1B: Easy Titer Calculation 
This section explains the calculations used to quantify the infectious baculovirus titer using the 
Titer less method described in section 5.4.2. 
First, the wells were scored for GFP activity. Wells that had any GFP were marked as positive, 
and those without as negative.  
Appendix 1B Table 1.1: Typical reading observed with the titerless assay.  
 1 2 3 4 5 6 7 8 9 10 11 12 
A + + + + + + + - - - -  
B + + + + + + - + - - -  
C + + + + + + + - - - -  
D + + + + + + + - + - -  
E + + + + + + + + - - -  
F + + + + + + - + - - -  
G + + + + + + + - - - -  
H + + + + + + + + - - -  
# + 8 8 8 8 8 8 6 4 1 0 0  
 
In columns 7 and 8 the % ratio of infected wells changes from above 50% to below 50%. To 
begin the infectious particle calculation, the proportionate distance (PD) must be calculated based 
on the % ratio above 50% infected and below.  
Proportionate  Distance   PD =    %  ratio  above  50% − 50%  ratio  above  50% − (%  ratio  below  50%) 
 
The % ratio above and below 50% was calculated as shown in Table 2. 
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Appendix 1B Table 1.2: Calculation for above and below 50% values 
 Virus  
Dilution 
Neg. Log Infected 
Wells 
Non-Inf. 
Wells 
Cumulative 
Inf. Wells 
Cumulative 
non-infected 
Wells 
% 
Infected 
1 1:1000 10-3      
2 1:5000 10-3.7      
3 1:25000 10-4.4      
4 1:125000 10-5.1      
5 1:625000 10-5.8      
6 1:3125000 10-6.5 8 0 19 0 100% 
7 1:15626000 10-7.2 6 2 11 2 85% 
8 1:78125000 10-7.9 4 4 5 6 45% 
9 1:390630000 10-8.6 1 7 1 13 7% 
 
Therefore, column 7 has 85% of the wells infected and column 8 has 45% and the PD is 
calculated as follows: 
PD = 85− 5085− 45 = 0.875 
To complete the calculation for infectious titer, the following calculations were then completed: PD   corrected = DP! = DP  ×  Difference  in  dilution  factor  at  turning  point   DP! = 0.875  ×   7.9− 7.2 = 0.61   Virus  Titer0.2ml = 10!"!!!"#!"  !"#$%"&'  !"  %  !"#$%  !"#$%  !"% Virus  Titer0.2ml = 10!.!"!!.!   = 10!.!" Virus  Titer = 3.23  ×  10!  pfu/ml 
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Appendix 2: HA Assay Calculations 
The HA titer is calculated based on the last well without agglutination of the red blood cells.  
Appendix 2 Table 2.1: Typical HA assay agglutination pattern 
Column 1 2 3 4 5 6 7 8 9 10 11 12 
Dilutions 1:1 1:2 1:4 1:8 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048 
             
 
 
Therefore, if column 6 were the last well with agglutination, where the dilution is 1/32, the 
amount of HA would be calculated as follows: Log  HA  units100  ul = log 32 = 1.5 log   𝐻𝐴  𝑢𝑛𝑖𝑡𝑠100𝑢𝑙  1000ul1  ml ×1.5log𝐻𝐴  𝑢𝑛𝑖𝑡𝑠100𝑢𝑙 = 10×1.5log𝐻𝐴  𝑢𝑛𝑖𝑡𝑠𝑚𝑙 = 2.5 log𝐻𝐴  𝑢𝑛𝑖𝑡𝑠𝑚𝑙  
2.5𝑙𝑜𝑔𝐻𝐴  𝑢𝑛𝑖𝑡𝑠𝑚𝑙 = 10!.!  𝐻𝐴 𝑢𝑛𝑖𝑡𝑠𝑚𝑙 = 316.23  𝐻𝐴 𝑢𝑛𝑖𝑡𝑠𝑚𝑙  
One HA unit is the equal to the minimum number of virus particles that cause complete 
agglutination. 
Based on NSEM quantification, particle concentration per HAU was calculated as follows: 
For the Sf9 system: Total  HA  Activity = HA  activity  from  BV+ HA  activity  from  VLP 
For Iodixanol fraction #2, the ratio of BV/VLP was 9:1 Total  HA  Activity = HA  activity  from  BV+ 19    HA  activity  from  BV  Total  HA  Activity = 109   (HA  activity  from  BV) 4520.7  HAUml HA  activity  from  BV 
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And for the activity from the VLPs, 5023  HAUml = 9   HA  activity  from  VLP +   HA  activity  from  VLP 5023  HAUml = 10  (HA  activiy  from  VLP) 502.3  HAUml = HA  activity  from  VLP 
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Appendix 3: SRID Calibration Curve 
To calculate the amount of HA in VLP, a standard curve must be made with known 
concentrations of HA protein. The standard used was recombinant HA from from Protein 
Sciences Corporation (USA). Concentrations used were 7.5, 15, 20 and 30 µg/ml. The diffusion 
ring diameter of each well was measured both horizontally and vertically. Then the average of 
was calculated and used to find the area of the ring. A standard curve based on these values was 
made (Appendix 3 Figure 3.1) to calculate the amount of HA in each sample. This standard curve 
was repeated each time the assay was done.  
 
Appendix 3 Figure 3.1: SRID standard curve with recombinant H1/A/PR/8/1934 protein from 
Protein Sciences corporation. 
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Appendix 4A: HEK 293 VLP Production Growth Curves 
Typical growth curves for VLP production at different MOIs in HEK 293 cells and non-
transduced cells are shown in Figure 1.0 of this section. Cells were transduced with baculovirus 
containing genes under CMV control just under 1.0x106 cells/ml and Butyric acid was added for 
a final concentration of 5mM to each VLP production but not the control. For transduced cultures, 
growth was greatly reduced, due to the addition of butyric acid, which halts cell growth. The 
control cells grew as they usually do, doubling after 24 hours and slowing growth after 2.0x106 
cells/ml. The viability profile is also shown in Figure 2.0 of this section, and illustrates that the 
control culture remained close to 100% viability after 48 hours, while VLP productions began to 
decrease in viability up to 80% at harvest. 
 
Appendix 4A Figure 4.1: Viable cell growth curve for HEK 293 VLP production 
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Appendix 4A Figure 4.2: Viability curve for HEK 293 VLP production 
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Appendix 4B: Sf9 VLP Production Growth Curves  
Typical growth curves for VLP production at different MOIs in Sf9 cells and uninfected cells are 
shown in Figure 1.0 of this section. Cells were infected with individual baculoviruses containing 
influenza genes under polh control at 2.0x106 cells/ml. For infected cultures, growth was greatly 
reduced, due to baculovirus infection, which halts cell growth. The control cells grew as they 
usually do, almost doubling every 24 hours. The viability profile is also shown in Figure 2.0 of 
this section, and illustrates that the control culture remained close to 100% viability after 48 
hours, while VLP productions began to decrease in viability up to 60% at harvest. In addition to 
growth and viability curves, average cell diameter of the cells during production is shown in 
Figure 3.0. The uninfected culture remain at a diameter of 15um for the duration of the 
experiment while the infected cultures cell size increases up to 19.5 um, indicating baculovirus 
infection.  
 
Appendix 4B Figure 4.1: Viable cell growth curve for Sf9 VLP production 
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Appendix 2B Figure 4.2: Viability curve for Sf9 VLP production 
 
 
Appendix 2B Figure 4.3: Cell diameter curve for Sf9 VLP production 
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Appendix 5: HEK 293 Western Blot Non-Specific Bands 
During process optimization, a contaminant band around 70 kDa was observed in the western 
blots of control cultures. This was worrisome because HA0 was expected to be at 70 kDa as well. 
However, during iodixanol purification it was verified that this contaminating band was simply 
overlapping with HA0. Figure 1.0 of this section shows the iodixanol western blot for HA with 
NIBSC anti-HA polyclonal antibody. The control well, to the right of the ladder, shows two 
bands above and below 75 kDa, none of which are believed to be HA0 as the control virus was 
produced in the presence of TPCK-trypsin, which cleaves HA0 into HA1 and HA2. VLPs 
however, will still have intact HA0 and lane 1 shows a large band at 75 kDa and another smaller 
one just under 75 kDa.  Lane 2 then reveals that three bands exist at  75 kDa, above, at and below. 
This is illustrated more closely in Figure 2.0.  Lanes 4 to 9 show that the middle band disappears 
and is present again in lanes 10-12. Additionally, the NA western blot that used the same 
secondary antibody (anti-sheep HRP) also has these bands above and below 75 kDa, but not the 
middle one (Figure 3.0). From these observations, this middle band is believed to be HA0. The 
other two bands may be heat shock proteins that are known to be expressed when cells are under 
stress, and have been shown to associate themselves with vesicles (De Maio, 2010).  
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Appendix 5 Figure 5.1: HA iodixanol western blot HEK 293 VLP 
 
 
Appendix 5 Figure 5.2: HEK 293 VLP HA iodixanol western blot, lanes 1 and 2 zoomed in 
 
 
Appendix 5 Figure 5.3: HEK 293 VLP NA iodixanol western blot, lanes 1 and 2 zoomed in  
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Appendix 6A: HEK 293 VLP NA and M1 Iodixanol Western Blots 
 
The iodixanol western blots for NA and M1 show the same information as the HA iodixanol 
western blot. Mainly, for the NA blot (Figure 1.0 in this section), there are NA signals at 55 kDa 
in fractions 1-4 and 8-10 (outlined by the orange box), and are strongest in the lower and upper 
fractions. The M1 blot (Figure 2.0) only has a band for M1 at 25 kDA, and bands at 75 kDa from 
the secondary antibodies. However, there is a band at 50 kDa that could be a M1 dimer.  
 
 
Appendix 6A Figure 6.1: HEK 293 VLP NA Iodixanol western blot 
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Appendix 6A Figure 6.2: HEK 293 VLP M1 Iodixanol western blot 
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Appendix 6B: Sf9 VLP NA and M1 Iodixanol Western Blots 
The iodixanol western blots for NA, M1 and GP64 for also correlate with the HA blot. In each 
blot, there are bands in every fraction, but they pool in higher concentrations in the bottom and 
top fractions, where there are VLPs are potentially free protein. The NA blot was overexposed, 
which is why there are white spots on the blot. NA has three bands above and below 50 kDa and 
at 25 kDa; M1 was found at 25 kDa and GP64 around 60 kDa.  
  
Appendix 6B Figure 6.1: Sf9 VLP NA iodixanol western blot 
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Appendix 6B Figure 6.2: Sf9 VLP M1 iodixanol western blot 
 
  
Appendix 6B Figure 6.3: Sf9 VLP GP64 iodixanol western blot 
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Appendix 7: Sf9 Optimization Western Blot  
The best condition was picked on the condition that each protein was found in the supernatant 
from western blot analysis. The different MOIs used for each baculovirus are outlined in Table 
7.1. 
Appendix 7 Table 7.1: List of MOIs used for influenza VLP production in Sf9 cells 
# on Western 
Blot 
(Pellet, Supernatant) 
HA NA M1 Total 
1, 2 0.1 0.1 0.1 0.3 
3, 4 0.5 0.5 0.5 1.5 
5, 6 1 1 1 3 
7, 8 1 0.1 0.1 1.2 
9, 10 0.1 0.1 1 1.2 
11, 12 0.1 1 0.1 1.2 
 
In Appendix 7 Figure 7.1, the western blot for HA from Sf9 VLP production is show. Lanes 1-6 
are from the pellet and supernatant of the first MOI experiment, where each baculovirus was 
added at the same MOI (Appendix 7 Table 7.1). From this western, it was clear that the majority 
of the HA protein found was still in the pellet (Lanes 1, 3, 5), so it was decided to try and change 
the MOIs and see if more influenza proteins were found in the supernatant. Lane 8 from 
Appendix 7 Figure 7.1 showed a band for HA0 in the supernatant. Additionally, lane 10 from 
Appendix 7 Figure 7.2 had a band for NA in the supernatant, but not an obvious band for HA0 in 
that condition. M1 was seen in each supernatant (Appendix 7 Figure 7.3), but in higher quantities 
in lane 10. From all this data, it was chosen to use an MOI of 1, 0.1 and 1 for HA, NA and M1, 
respectively, to give the highest chance of influenza proteins in the supernatant, in the form of 
VLPs.   
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Appendix 7 Figure 7.1: HA western blot of Sf9-VLP productions at different MOIs with NIBSC 
anti-HA 
 
 
Appendix 7 Figure 7.2: NA western blot of Sf9-VLP productions at different MOIs with NIBSC 
anti-NA 
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Appendix 7 Figure 7.3: M1 western blot of Sf9-VLP productions at different MOIs with NIBSC 
anti-NA 
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Appendix 8: HPLC Method for In-process VLP Analysis 
A high-throughput method that is able to analyze crude samples and that can detect and ideally 
quantify total VLP particles is needed. High Performance Liquid Chromatography (HPLC) has 
been previously used as a quantification method for total baculovirus particles (Transfiguracion, 
Mena, Aucoin, & Kamen, 2011) and as a process analytical technology (PAT) tool (Rathore, Yu, 
Yeboah, & Sharma, 2008). It has the potential to analyze crude material in large quantities, 
making this method suitable for particle detection/quantification during different stages of 
process development. There already exists an HPLC based method for HA protein quantification 
that is currently in use or in development for use as an in-process method (Lorbetskie et al., 
2011), but it does not give information on the total amount of particles. The following section 
outlines the advances made on VLP detection using an HPLC method with an ion exchange 
monolith column for total influenza particle quantification. The goal for these experiments was to 
investigate if total VLPs could be detected using an existing in-house total particle influenza 
quantification method. Considering the difficulties experienced during process optimization 
(cumbersome protocols, low yields and poor limit of detections for existing influenza 
quantification techniques), this method could be a valuable tool during process development and 
could give further insight into the development of an HPLC quantification method. 
Appendix 8.1 Monolith Column 
A convective interactive media (CIM) Quaternary Amine (QA) monolith column (CIMac™ QA-
0.1 Analytical column, BiaSeparations, Austria) was chosen based on its potential to purify large 
particles, such as viruses (Barut, Podgornik, Urbas, & Al, 2008), to circumvent resin based 
chromatographic methods, which cannot be used due to virus size (20-750 µm) (Oksanen, 
Domanska, & Bamford, 2012).   
Appendix 8.2 HPLC Method for Influenza Quantification Method 
A method was developed in Dr Kamen’s group for total particles influenza virus quantification 
(data not shown) and is still in development The method consisted of loading virus or VLP 
samples onto the column at a salt concentration of 200mM. At this concentration, it was found 
that particles are able to bind to the column, but free proteins cannot, allowing them to flow 
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through. Next, elution occured at three different salt concentrations of 450mM, 650mM and 1M 
NaCl, and resulted in three separate peaks labeled Peak 1, Peak 2 and Peak 3 (Appendix 8 Figure 
8.1). Peak 2 has been identified as infectious influenza particles from TCID50 and western blot 
measurements of the eluted sample. The peak at 1M is hypothesized to be DNA based on its 
260/280 ratio of approximately 2 with UV (Held, 2006). It remains unknown what is eluting in 
the 450 mM NaCl peak, but we estimate it could be HEK 293 system vesicles or large protein 
aggregates that were able to bind during the 200mM NaCl loading step. The detection method 
used was fluorescence at ex290/em335, which is the intrinsic fluorescence of the HA protein 
tryptophan residues (Ohnishi, 1983), and UV detection at 260 and 280 nm. 
 
 
Appendix 8 Figure 8.1: Elution profile for SCC-A/H1N1/Puerto Rico/8/1934 
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Appendix 8.3 Application to VLPs 
Appendix 8.3.1 Detection of HEK 293 VLPs 
Crude VLP supernatant, SCC and iodixanol purified VLPs all gave the same profile as influenza 
virus when using the same method as described above. Appendix 8 Figure 8.2 is a representation 
of the profiles generally obtained. The peak at 450mM NaCl (Peak 1) had a 260/280 ratio of 0.89, 
which indicated that this peak contained mainly proteins.  The peak at 650mM NaCl (Peak 2), 
which was the peak identified as infectious influenza virus, had a 260/280 ratio of 1.3-1.5, which 
indicates that this peak contained mainly proteins with some associated nucleic acid. Finally, the 
peak at 1M NaCl has a 260/280 ratio of 1.8, indicating it contains mainly nucleic acids. A ratio of 
1.3-1.5 is close to the ratio for viruses (Tancevski, Wehinger, Patsch, & Ritsch, 2006), indicating 
that there was nucleic acid co-eluting with the VLPs. When each peak was collected (3x 150ul 
sample, crude supernatant), the western blot for HA, NA and M1 was unclear, with many bands 
present in each peak probably due to protein degradation from TCA precipitation, which was 
required due to dilution during peak collection. Another possibility for degradation of the VLPs 
is the high salt concentration present in the elution buffer, as nothing is known to date about 
influenza VLP stability in high salt concentrations. Nevertheless, we chose to move forward 
focusing on Peak 2 on the basis that it was identified as infectious influenza virus, making the 
assumption that Peak 3 is nucleic acids and that Peak 1 could either be protein aggregates, VLPs 
or vesicles based on their 260/280 ratios.  
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Appendix 8 Figure 8.2: Elution profile for HEK 293 SF 25x concentrated sucrose cushion 
purified VLP 
When comparing the area of Peak 2 from crude supernatants, there was a correlation found 
between the peak area and the western blot signals from the MOI experiments. Appendix 8 
Figure 8.3 shows a histogram of Peak 2 areas for MOIs of 1, 20, 60, 120 and 200 compared to the 
HA western blot profile for different. In the western blot, MOIs of 60 and 120 had the highest 
intensity level, suggesting that the greatest amount of HA was produced using these conditions. 
An MOI of 60 has the largest peak area followed by an MOI of 120 then 200, suggesting that an 
MOI of 60 produced the greatest amount of VLPs. Paring these two methods allows for selection 
of the condition that produces the highest amount of VLPs, not just the greatest amount of HA 
protein. This is important because it cannot be assumed that the condition that produces the 
greatest amount of HA correlates direction to the greatest amount of VLPs. However, there is one 
aspect of this result that needs to be mentioned, and that is the peaks for MOIs of 1 and 20. In 
western blot profile there are very slight bands present for these conditions, but a considerable 
peak from the HPLC method. This background could be from contaminating vesicles that also 
contain proteins with the same intrinsic fluorescence as HA, especially since such a low amount 
of HA was on the western blot. This can be confirmed by applying the control supernatant to the 
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HPLC column. Considering that intrinsic fluorescence is based on tryptophan, tyrosine and 
phenylalanine residues, host cell proteins or vesicle proteins could emit a signal if they contain 
these residues.  
  
 
 
 
 
 
Appendix 8 Figure 8.3: Peak areas of 650mM NaCl elution (Peak 2) at different MOIs for HEK 
293 VLP production and their corresponding HA western blot signal.  
NIBSC anti-HA anitbodies. Numbers 1-5 corresponds to MOIs of 1-200, respectively.  
The final observation found from these experiments was the difference in the peak area between 
crude supernatant and SCC-VLP samples. Appendix 8 Figure 8.4 illustrates this difference 
clearly with the supernatant peak area represented with the bar on the left and the sucrose cushion 
peak area on the right. 
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Appendix 8 Figure 8.4: Peak 2 area of crude supernatant and sucrose cushion purified HEK 293 
VLPs measured by 290/330  
The calculated yield from the sucrose cushion is 6.6%. An explanation for this observation may 
lie in the NSEM pictures from the sucrose cushion purified VLP samples. Appendix 8 Figure 8.5 
shows a zoomed out image of the sucrose cushion VLPs and influenza virus A H1N1/Puerto 
Rico/8/1934 produced in HEK 293 cells. The VLP sample (A, VLPs labeled with black arrows) 
has a lot of debris that could be broken VLPs unable to withstand the concentration step, thus 
leading to the major decrease in peak area in the sucrose cushion sample (debris labeled with 
white arrows). The influenza virus sample shows much less cell debris than the VLP sample for 
comparison (Appendix 8 Figure 8.5 B). 
 Appendix 8 Figure 8.5: NSEM images of sucrose cushion purified HEK 293 VLPs (A) and 
influenza virus A/H1N1/Puerto Rico/8/1934 (B).  
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Appendix 8.3.2 Application to Sf9 VLPs 
When Sf9 VLPs were applied on the HPLC with the method developed for influenza virus, a 
similar profile was obtained as for HEK 293 VLPs. Both crude, sucrose cushion and iodixanol 
samples were tested. Peak 1 had a 260/280 ratio of 1.3, Peak 2 and Peak 3 both had a ratio of 1.6. 
A 260/280 ratio of 1.3 is close to that of a virus (Tancevski et al., 2006) and is very close to the 
ratio found by Transfiguracion et al (Transfiguracion et al., 2011) in their baculovirus 
quantification protocol using an anion exchange column with elution at 480mM NaCl. 
Additionally, Gerster et al.(2013) found when purifying baculovirus with a CIM QA monolithic 
column, that the majority of BV eluted at 440mM NaCl, which is very close to the peak found 
here at 450mM NaCl. It is therefore possible for baculovirus and influenza VLP separation, under 
the assumption that influenza VLPs should elute in Peak 2 at 650 mM salt and the BV particles at 
around 450mM NaCl. A 260/280 ratio of 1.6 indicates that nucleic acids were eluting with the 
VLPs, as was the case for HEK293 VLPs. When crude supernatant and sucrose cushion VLPs 
were run on the column, there was not such a drastic decrease in peak area like there was 
observed for the HEK 293 SF system (Appendix 8 Figure 8.6), with a yield of 62%. When 
comparing the zoomed out image of the NSEM image of Sf9 sucrose cushion VLPs (Appendix 8 
Figure 8.7) to those from HEK 293 SF, it is clear there is much less debris present (indicated with 
white arrows), besides the obvious contamination from baculovirus, potentially indicating that 
Sf9 VLPs have a greater stability. 
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Appendix 8 Figure 8.6: Peak 2 area of crude supernatant vs. sucrose cushion purified Sf9 VLPs 
measured by UV 280nm.  
 
Appendix 8 Figure 8.7: NSEM image zoomed out of sucrose cushion Sf9 VLPs.  
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